JP7030109B2 - CD3 binding antibody - Google Patents

Description

Cross-reference This application is a US provisional patent application No. 62 / 394,360 filed on September 14, 2016, and a US provisional patent application No. 62 / 491,908 filed on April 28, 2017. All of these applications are incorporated herein by reference in their entirety.

Background The body's immune system serves as a defense against infections, injuries and cancer. Two separate but interrelated systems, the humoral and cell-mediated immune systems, work together to protect the body. The humoral system is mediated by soluble factors called antibodies to neutralize products that are perceived as foreign in the body. In contrast, cell-mediated systems include cells such as T cells and macrophages that remove and neutralize foreign invaders.

Activation of T cells is important for stimulating the immune response. T cells exhibit immunological specificity and lead to most cell-mediated immune responses. T cells do not secrete antibodies, but are required for antibody secretion by B lymphocytes. T cell activation requires the involvement of T cell receptor complexes and numerous cell surface molecules such as CD4 or CD8 molecules. The antigen-specific T cell receptor (TcR) consists of a disulfide bond heterodimer, a chained membrane glycoprotein, alpha and beta (α and β), or gamma and delta (γ and δ). The TcR is non-covalently linked to a complex of invariant proteins called CD3.

T cells are known to exert potent antitumor effects in a number of experimental settings. Antibodies capable of effectively mobilizing T cells against tumor cells are, for example, as bispecific antibodies directed to tumor-related antigens (TAAs) and agonist T cell membrane proteins such as TCR / CD3 complexes and CD28. It was available. These bispecific antibodies can activate T cells regardless of their TCR specificity, resulting in specific lysis of cells with their respective TAAs.

However, although anti-CD3 bispecific antibodies can direct T cell-mediated lysis to malignant cells, clinical trials with CD3-based bSAbs have shown high toxicity to patients. Non-specific T cell activation from bSAb is antigen-independent due to Fc / Fc receptor (FcR) interactions, or antigen-dependent when the antigen is expressed in both normal and tumor cells. Can occur. Both mechanisms may have been the cause of the toxicity observed in previous clinical trials. See, for example, Link et al. (1998) Int. J. Cancer 77 (2): 251-6; Durben et al. Molecular Therapy (2015); 234, 648-655. Due to the resulting cytokine release syndrome, it has been an important block in the development of these antibodies for therapeutic purposes.

The interaction of the T cell receptor (TCR) with its peptide-MHC ligand determines T cell activity. The binding properties of this interaction have been studied in great detail and have been shown to regulate T cell function. The intensity and properties of the TCR-peptide / MHC interaction determine whether T cells exert effector function or are inactivated and deleted. Antibodies to CD3 activate T cells by altering the conformation of the CD3ε chain and depending on the epitope that may have either an agonistic or antagonistic effect on T cells (Yoon et al. , 1994 Immunoty 1: 563-569). Given the significant side effects of many T cell agonists, it may be preferable to maintain a strong antitumor effect while reducing the release of pro-inflammatory cytokines. However, partial agonist anti-CD3 antibodies alter the CD3ε chain suboptimally to result in ineffective signaling, and most anti-CD3 antibodies are fully agonists for both pathways. It is unclear whether these effector functions can be separated. Many existing anti-CD3 antibodies (eg, SP-34, UCHT1, OKT3) have affinities in the range of 1-50 nM KD, which may not be optimal for therapeutic use.

CD3 specific antibodies, and bispecific antibodies derived thereto, are provided by the present invention.

Published CD3 antibodies are, for example, US Pat. Nos. 5,585,097, 5,929,212, 5,968,509, 6,706,265, 6,750,325, 7,381,803. No. 7,728,114. Bispecific antibodies with CD3 binding specificity are disclosed, for example, in US Pat. Nos. 7,262,276, 7,635,472, 7,862,813, and 8,236,308. Each is specifically incorporated herein by reference.

U.S. Pat. No. 5,585,097 U.S. Pat. No. 5,929,212 U.S. Pat. No. 5,968,509 U.S. Pat. No. 6,706,265 U.S. Pat. No. 6,750,325 U.S. Pat. No. 7,381,803 U.S. Pat. No. 7,728,114 U.S. Pat. No. 7,262,276 U.S. Pat. No. 7,635,472 U.S. Pat. No. 7,862,813 U.S. Pat. No. 8,236,308

Link et al. (1998) Int.J.Cancer 77 (2): 251-6 Durben et al. Molecular Therapy (2015); 234, 648-655 Yoon et al. , 1994 Immunity 1: 563-569

Overview The composition and method of use thereof are provided for a family of closely related antibodies that bind to CD3 and activate signal transduction via CD3 (eg, activation of CD3 ⁺ T cells). The family of antibodies comprises a set of CDR sequences as defined herein. The antibody family provides many benefits that contribute to its usefulness as a clinical therapeutic agent (s). Antibodies within the family include members with a range of binding affinities, allowing selection of specific sequences with the desired affinities. The ability to fine-tune affinity is of particular importance in controlling the level of CD3 activation in the individual being treated, thereby reducing toxicity.

In some embodiments, the anti-CD3 antibody may have an affinity (KD) for CD3 in the range of about ^10-6 to about ^10-11 .

Anti-CD3 antibodies with an affinity (KD) of 50 nM or higher, 100 nM or higher, 500 nM or higher, or 1 μm M or higher are toxic while more closely mimicking the TCR / MHC interaction and maintaining effective tumor cytolysis. It may be desirable to minimize the release of cytokines. In some embodiments, the anti-CD3 antibody is characterized by, for example, binding to competent T cells for the release of IL-2 and IFNγ, which reduces the tendency to induce the release of cytokines. Or selected. Antibodies are, for example, antibodies that induce less than about half of the maximum cytokine release observed for family members in comparative assays within the family of antibody sequences described herein, for killing tumor cells and releasing cytokines. It may be selected for therapeutic use that optimizes the reduction, and may be, for example, less than the maximum of about 25% or less observed for family members in comparative assays. In some embodiments, bispecific or multispecific antibodies are provided that include at least heavy chain variable regions from the antibody family and may include the heavy and light chain variable regions provided herein. Bispecific antibodies include at least heavy chain variable regions of antibodies specific for proteins other than CD3, and may include heavy and light chain variable regions. In some such embodiments, the second antibody specifically binds to a tumor-related antigen, such as a target antigen such as an integrin, a pathogen antigen, a checkpoint protein, and the like. Various bispecific antibody forms, including, but not limited to, single-stranded polypeptides, double-stranded polypeptides, triple-stranded polypeptides, quadruplex polypeptides, and multiples thereof. It is within the scope of the invention.

Each of the CD3-specific antibodies comprises a VH domain containing the CDR1, CDR2 and CDR3 sequences in the human VH framework. The Family 2 CDR sequences, as an example, are approximately amino acid residues 26-33, 51-58 and 97, respectively, for CDR1, CDR2 and CDR3 of the provided exemplary variable region sequences set forth in SEQ ID NOs: 1-18, respectively. Can be located in the region of ~ 112. It will be appreciated by those skilled in the art that if different framework sequences are selected, the CDR sequences can be in different positions, but the order of the sequences generally remains the same.

ここで、
Ｘ_５は、任意のアミノ酸であってもよく、いくつかの実施形態において、Ｘ_５は、Ｄ、ＡまたはＨであり、いくつかの実施形態において、Ｘ_５は、Ｄである。
Ｘ_６は、任意のアミノ酸であってもよく、いくつかの実施形態において、Ｘ_６は、ＤまたはＮであり、いくつかの実施形態において、Ｄ_６は、Ｄである。
いくつかの実施形態において、ファミリー２の抗ＣＤ３抗体のＣＤＲ１配列は、配列番号１～１８、残基２６～３３のいずれかに記載の配列を含む。

いくつかの実施形態において、ファミリー２の抗ＣＤ３抗体のＣＤＲ２配列は、配列番号１～１８、残基５１～５８のいずれかに記載の配列を含む。

ここで、
Ｘ_９’’は、任意のアミノ酸であってもよく、いくつかの実施形態において、Ｘ_９’’は、ＤまたはＳであり、いくつかの実施形態において、Ｘ_９’’は、Ｄであり、
Ｘ_１１’’は、任意のアミノ酸であってもよく、いくつかの実施形態において、Ｘ_１１’’は、ＲまたはＳであり、
Ｘ_１２’’は、任意のアミノ酸であってもよく、いくつかの実施形態において、Ｘ_１２’’は、ＬまたはＲである。 The CDR sequence of a Family 2 antibody may have the following sequence formula: X represents a variable amino acid and may be a specific amino acid as shown below.

here,
X ₅ may be any amino acid, in some embodiments X ₅ is D, A or H and in some embodiments X ₅ is D.
X ₆ may be any amino acid, in some embodiments X ₆ is D or N, and in some embodiments D ₆ is D.
In some embodiments, the CDR1 sequence of a Family 2 anti-CD3 antibody comprises the sequence set forth in any of SEQ ID NOs: 1-18, residues 26-33.

In some embodiments, the CDR2 sequence of a Family 2 anti-CD3 antibody comprises the sequence set forth in any of SEQ ID NOs: 1-18, residues 51-58.

here,
X _{9 ″} may be any amino acid, in some embodiments X _{9 ″} is D or S, and in some embodiments X _{9 ″} is D. ,
X _{11 ″} may be any amino acid, and in some embodiments, X _{11 ″} is R or S.
X _{12 ″} may be any amino acid, and in some embodiments, X _{12 ″} is L or R.

を有し、式中、Ｘ_１１”及びＸ_１２”は、上記で定義した通りである。いくつかの実施形態において、ファミリー２の抗ＣＤ３抗体のＣＤＲ３配列は、配列番号１～１８、残基９７～１１２のいずれかに記載の配列を含む。いくつかの実施形態において、ファミリー２の抗体のＣＤ３結合ＶＨドメインは、軽鎖可変領域ドメインと対になる。このようないくつかの実施形態において、軽鎖は、固定された軽鎖である。 In some embodiments, the CD3 sequence of the family 2 anti-CD3 antibody is the formula.

In the formula, X _{11 "} and X _12" are as defined above. In some embodiments, the CDR3 sequence of a Family 2 anti-CD3 antibody comprises the sequence set forth in any of SEQ ID NOs: 1-18, residues 97-112. In some embodiments, the CD3-bound VH domain of a Family 2 antibody is paired with a light chain variable region domain. In some such embodiments, the light chain is a fixed light chain.

In some embodiments, the light chain comprises a VL domain having CDR1, CDR2 and CDR3 sequences in the human VL framework. The CDR sequence may be that of SEQ ID NO: 19. In some embodiments, the CDR1 sequence comprises amino acid residues 27-32, 50-52, 89-97 for CDR1, CDR2, CDR3, respectively.

In some embodiments, the CDR sequences of the antibodies of the invention are at least 85% identity, at least 90% identity, at least to a set of CDR sequences or CDR sequences set forth in SEQ ID NOs: 1-18. A sequence having 95% identity, at least 99% identity. In some embodiments, the CDR sequences of the invention are substituted with one, two, three or more amino acids for any one of the CDR sequences of SEQ ID NOs: 1-18 or a set of CDR sequences. include. In some embodiments, amino acid substitutions (s) are at positions 5 or 10 of CDR1, positions 2, 6 or 7 of CDR2, positions 1 and 8 of CDR3 with respect to the family 2 equations described above. One or more of ranks, 9th or 10th.

In some embodiments, the bispecific antibodies of the invention are paired with a light chain and include the CD3 binding variable regions described herein. In some embodiments, the light chain comprises a variable region sequence set forth in SEQ ID NO: 19, or a variable region comprising a set of CDR sequences and framework sequences of SEQ ID NO: 19. Various Fc sequences are used that include, but are not limited to, human IgG1, IgG2a, IgG2b, IgG3, IgG4, and the like. In some embodiments, the second arm of the bispecific antibody comprises a variable region that specifically binds to a tumor-related antigen. In some embodiments, the second arm of the bispecific antibody comprises a variable region that specifically binds BCMA. In some embodiments, the anti-BCMA arm is, for example, a single chain variable region as shown in FIG. 2B. In some embodiments, the anti-BCMA arm comprises the variable region sequence set forth in SEQ ID NO: 20, or the tandem variable region sequence set forth in SEQ ID NO: 21. The Fc sequence of the anti-BCMA arm may be, but is not limited to, human IgG1, IgG2a, IgG2b, IgG3, IgG4 and the like. The CDR sequence may be the CDR sequence contained in SEQ ID NO: 20. In some embodiments, the CDR sequence comprises amino acid residues 26-33, 51-58, 97-108 for CDR1, CDR2, CDR3, respectively.

In other embodiments, antibodies or antibody-like proteins such as monospecific, bispecific, etc. comprising at least the CD3-binding VH domain of the invention, at least the CD3-binding VH domain of the invention, and pharmaceutically acceptable. Pharmaceutical compositions containing excipients are provided. The composition may be lyophilized, suspended in a solution or the like, or provided as a unit dose formulation.

In some embodiments, methods for the treatment of cancer are provided, in which an effective amount of an antibody of the invention, such as unispecific, bispecific, etc., is administered to an individual in need thereof. Including doing. When the antibody is bispecific, the second antigen binding site may specifically bind to a tumor antigen, checkpoint protein, or the like. In various embodiments, the cancer is ovarian cancer, breast cancer, gastrointestinal tract, brain tumor, head and neck cancer, prostate cancer, colon cancer, lung cancer, leukemia, lymphoma, sarcoma, cancer, nerve cell tumor, squamous cell carcinoma, germ. It is selected from the group consisting of cell tumors, metastases, undifferentiated tumors, sperm epithelioma, melanoma, myeloma, neuroblastoma, mixed cell tumors, and neoplasm formation by infectious pathogens.

In some embodiments, a method for the treatment of an infectious disease is provided, wherein the method administers an effective amount of an antibody of the invention, such as unispecific, bispecific, etc., to an individual in need thereof. Including doing. If the antibody is bispecific, the second antigen binding site may specifically bind to a pathogen antigen, eg, a bacterium, virus or parasite.

In another embodiment, the production of bispecific antibodies of the invention comprising expressing an antibody sequence, eg, one or more light chain coding sequences, or one or more heavy chain coding sequences in a single host cell. Methods are provided. In various embodiments, the host cell may be a prokaryotic cell or a eukaryotic cell such as a mammalian cell.

The present invention is best understood from the following detailed description when read in conjunction with the accompanying drawings. The patent or application file contains at least one drawing made in color. A copy of this patent or publication of the patent application with color drawings (s) will be provided by the Office upon request and payment of the required fees. It is emphasized that, according to common practice, the various features of the drawing are not at the same scale. Conversely, the dimensions of the various features are optionally scaled up or down for clarity. The drawings include the following figures.

1A-1C. FIG. 1A shows the alignment of CDR1, 2 and 3 regions of members of antibody family 2 of SEQ ID NOs: 1-18 that specifically bind to human CD3, corresponding to residues 26-33, 51-58 and 97-112. Is shown. FIG. 1B shows the CDR1, 2 and 3 regions of the fixed light chain (SEQ ID NO: 19), as well as exemplary anti-BCMA sequences (SEQ ID NO: 20 and SEQ ID NO: 21). FIG. 1C provides the CDR sequence of the reference anti-CD3 antibody (SEQ ID NO: 22), ID 304704. 2A-2E. Schematic diagram of a bispecific human antibody. 2A is an anti-CD3: anti-tumor antigen bispecific antibody (all three unique chains) having a common light chain. 2B is an anti-CD3: anti-tumor antigen bispecific antibody with two unique light chains (all four unique chains). 2C is an anti-tumor antigen bispecific antibody (three unique chains) having an anti-CD3: heavy chain-only tumor antigen binding domain chain. 2D is an anti-tumor antigen bispecific antibody (all three unique chains) having an anti-CD3: ScFv tumor antigen binding domain. 2E is an anti-tumor antigen bispecific antibody (all three unique chains) having an anti-CD3: ScFv anti-CD3 binding domain. 2A-2E. Schematic diagram of a bispecific human antibody. 2A is an anti-CD3: anti-tumor antigen bispecific antibody (all three unique chains) having a common light chain. 2B is an anti-CD3: anti-tumor antigen bispecific antibody with two unique light chains (all four unique chains). 2C is an anti-tumor antigen bispecific antibody (three unique chains) having an anti-CD3: heavy chain-only tumor antigen binding domain chain. 2D is an anti-tumor antigen bispecific antibody (all three unique chains) having an anti-CD3: ScFv tumor antigen binding domain. 2E is an anti-tumor antigen bispecific antibody (all three unique chains) having an anti-CD3: ScFv anti-CD3 binding domain. The table of anti-CD3 family 2 data summarizes the behavior of anti-CD3 antibodies in unispecific and bispecific forms. Column 1 shows the SEQ ID NOs of the anti-CD3VH sequence. Column 2 shows the MFI values for Jurkat cell junctions of parental monospecific anti-CD3. Column 3 shows the MFI values for cynomolgus monkey T cell binding of parental monospecific anti-CD3. Column 4 shows the names of aCD3: aBCMA bispecific antibodies. Column 5 shows a picogram of IL-2 released by pan-T cells stimulated by a bispecific antibody that binds to BCMA proteins, coated with plastic at the indicated dose. Column 6 shows a picogram of IL-6 released by pan-T cells stimulated by a bispecific antibody that binds BCMA proteins, coated with plastic at the indicated dose. Column 7 shows a picogram of IL-10 released by pan-T cells stimulated by a bispecific antibody that binds BCMA proteins, coated with plastic at the indicated dose. Column 8 shows picograms of IFN-γ released by pan-T cells stimulated by bispecific antibodies that bind BCMA proteins, coated with plastic at the indicated dose. Column 9 shows a picogram of TNFα released by pan-T cells stimulated by a bispecific antibody that binds to BCMA proteins, coated with plastic at the indicated dose. Column 10 shows _EC50 of bispecific antibody-mediated U266 tumor cytolysis in the presence of human pan-T cells. Column 11 shows the lysis percent of U266 tumor cells at a dose of 333 ng / mL bispecific antibody and bispecific antibody in the presence of human pan-T cells. Column 12 shows the protein binding affinity of the anti-CD3 arm of the bispecific antibody as measured by the octet. Column 13 shows MFI values for Jurkat cell binding of bispecific antibodies. Bispecific antibody-mediated tumor cytolysis. Seven αCD3_fam2: aBCMA bispecific antibodies, each with a unique anti-CD3 arm and a common anti-BCMA arm, were tested for their ability to kill U266BCMA + tumor cells by redirection of activated primary T cells. In this experiment, BCMA-expressing U266 cells were mixed with activated pan-T cells in a 10: 1 E: T ratio with the addition of bispecific antibodies. The X-axis shows the concentration of the antibody used, and the Y-axis shows the% lysis of tumor cells 6 hours after the addition of the antibody. The killing activity of bispecific U266 correlated with the release of IL-2. A scatter plot shows a comparison of bispecific antibody-mediated tumor cytolytic activity with IL-2 cytokine release. The correlation between IL-2 production and U266 tumor cell lysis is R ² = 0.37. The killing activity of bispecific U266 correlated with the release of IFN-γ. A scatter plot shows a comparison of bispecific antibody-mediated tumor cytolytic activity with IFN-γ cytokine release. The correlation between IFN-γ production and U266 tumor cell lysis is R ² = 0.53. The killing activity of bispecific U266 correlated with anti-CD3 binding affinity. A scatter plot shows a comparison of bispecific antibody-mediated U266 tumor cytolytic activity with anti-CD3 binding affinity. The correlation between killing EC50 of U266 and protein binding affinity is R ² = 0.93. 8A-8D. Bispecific antibody-mediated tumor cytolysis. αCD3_F1F: aBCMA bispecific antibodies were assayed for their ability to kill three different BCMA + tumor cells and one BCMA negative cell line by redirection of activated primary T cells. In this experiment, tumor cells were mixed with activated pan-T cells at a 10: 1 E: T ratio with the addition of bispecific antibodies. 8A indicates the killing of RPMI-8226 cells, 8B indicates the killing of NCI-H929 cells, 8C indicates the killing of U-266 cells, and 8D indicates the killing of the negative control K562 cells. The X-axis shows the concentration of the antibody used, and the Y-axis shows the% lysis of tumor cells 6 hours after the addition of the antibody. 9A-9D. Bispecific antibody-mediated IL-2 release. Levels of IL-2 cytokine release were measured after dormant human T cells were cultured in increasing doses of various tumor cell lines and αCD3_F1F: aBCMA bispecific antibodies. 9A showed the release of IL-2 stimulated by RPMI-8226 cells, 9B showed the release of IL-2 stimulated by NCI-H929 cells, and 9C showed the release of IL-2 stimulated by U266 cells. 9D indicates the release of IL-2 stimulated by the negative control K562 cells. 10A-10D. Bispecific antibody-mediated IFNγ release. Levels of IFN-γ cytokine release were measured after dormant human T cells were cultured in increasing doses of various tumor cell lines and αCD3_F1F: aBCMA bispecific antibodies. 10A shows the release of IFNγ stimulated by RPMI-8226 cells, 10B shows the release of IFNγ stimulated by NCI-H929 cells, and 10C shows the release of IFN-γ stimulated by U-266 cells. 10D indicates the release of IFNγ stimulated by the negative control K562 cells.

Detailed Description To facilitate the understanding of the present invention, some terms are defined below.

Prior to the description of the Activators and Methods, it is understood that the invention is not limited to the particular methodologies, products, devices and factors described and such methods, devices and formulations may of course vary. It should be. It should also be understood that the terms used herein are for illustration purposes only and are not intended to limit the scope of the invention, which is limited solely by the appended claims. ..

As used herein and in the appended claims, the singular forms "a", "an" and "the" shall include multiple referents unless explicitly stated otherwise in the context. Please note. Thus, for example, reference to a "drug candidate" refers to one or a mixture of such candidates, and reference to "the method" includes reference to equivalent steps and methods known to those of skill in the art.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. All publications described herein are referenced herein for the purpose of describing and disclosing the devices, formulations, and methodologies that may be used in connection with the inventions described herein. Incorporated herein by.

If a range of values is provided, each intervening value shall be with the upper and lower limits of that range within the stated range included within the scope of the invention, unless otherwise indicated in the context. It is understood to be one tenth of the lower bound unit between any other stated or intervening value. The upper and lower limits of these smaller ranges may be independently included in the smaller range and are included within the invention in the range described, subject to any specifically excluded limits. .. Where the stated ranges include one or both of the limits, the scope of the present invention also excludes any of those included limits.

In the following description, a number of specific details are given to provide a more complete understanding of the invention. However, it will be apparent to those skilled in the art that the present invention may be practiced in the absence of one or more of these particular details. In other examples, features and procedures well known to those of skill in the art are not described to avoid obscuring the invention.

In general, conventional methods of protein synthesis, recombinant cell culture and protein isolation, and recombinant DNA technology within the skill of one of ordinary skill in the art are employed in the present invention. Such techniques are well described in the literature, for example, Maniatis, Fritsch & Sambrook, Molecular Cloning: A Laboratory Manual (1982); Sambrook, Russel and Samblook, Mollok, Mollok, Molecular (Molla) and Harlow, Using Antibodies: A Laboratory Manual: Portable Protocol No. I, Cold Spring Harbor Laboratory (1998); and Hallow and Labor

Definition "Contains" means that the enumerated elements are required in the composition / method / kit, while the other elements form the composition / method / kit, etc. within the scope of the claims. May be included for.

By "essentially consisting of" is a limitation of the range of compositions or methods described in a particular material or process that does not substantially affect the basic and novel features (s) of the invention. Means.

By "consisting of" is meant exclusion from the composition, method or kit of any element, process or ingredient not specified in the claims.

The terms "treatment", "treat" and the like are commonly used herein to mean obtaining the desired pharmacological and / or physiological effect. The effect can be prophylactic in that it completely or partially prevents the disease or its symptoms, and / or is therapeutic in terms of the partial or complete cure of the disease and / or the adverse effects caused by the disease. Can be. As used herein, "treatment" includes any treatment of a disease in a mammal, wherein the disease is in a subject who may (a) predispose to the disease but has not yet been diagnosed with it. It includes preventing it from occurring, (b) inhibiting the disease, i.e., preventing its onset, or (c) alleviating the disease, retreating the disease. Therapeutic agents may be administered before, during or after the onset of the disease or injury. Treatment of ongoing diseases, in which treatment stabilizes or reduces unwanted clinical symptoms of the patient, is of particular interest. It is desirable that such treatment precede the complete loss of function in the affected tissue. Subject therapy may be administered during the symptom stage of the disease and, in some cases, after the symptom stage of the disease.

A "therapeutically effective amount" is intended the amount of activator required to provide a therapeutic benefit to the subject. For example, a "therapeutically effective amount" is an amount that induces, improves, or otherwise causes, or improves tolerance to a disease-related pathological condition, disease progression or physiological condition. ..

The terms "subject," "individual," and "patient" are used interchangeably herein to refer to a mammal that is evaluated and / or treated for treatment. In one embodiment, the mammal is a human. The terms "subject," "individual," and "patient" include, but are not limited to, individuals with cancer, individuals with autoimmune diseases, individuals with pathogen infection, and the like. The subject may be a human, but also includes other mammals, in particular mammals useful as experimental models of human disease, such as mice, rats and the like.

The terms "cancer", "neoplasm", and "tumor" are used interchangeably herein and are autonomous, such as exhibiting an abnormal proliferation phenotype characterized by a significant loss of control over cell proliferation. A cell that exhibits unregulated proliferation. Cells targeted for detection, analysis or treatment in the present application include precancerous (eg, benign), malignant, pre-metastatic, metastatic and non-metastatic cells. Cancer of virtually any tissue is known. The phrase "cancer load" refers to the quantum of the cancer cell or cancer volume of interest. Therefore, reducing the cancer load means reducing the number or volume of cancer cells in the subject. As used herein, the term "cancer cell" refers to any cell that is or is derived from a cancer cell, eg, a clone of a cancer cell. Many types of cancer, including solid tumors such as cancers, sarcomas, glioblastomas, melanomas, lymphomas, myelomas, and especially circulating cancers such as leukemias including B-cell leukemias, T-cell leukemias, etc. Known to those in the art. Examples of cancer include, but are not limited to, ovarian cancer, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, Includes thyroid cancer, kidney cancer, cancer, melanoma, head and neck cancer, and brain tumor.

"Antibody-dependent cell-mediated cytotoxicity" and "ADCC" are non-specific cytotoxic cells that express Fc receptors such as natural killer cells, neutrophils and macrophages to bind antibodies on target cells. A cell-mediated reaction that recognizes and causes lysis of target cells. ADCC activity can be assessed using methods such as those described in US Pat. No. 5,821,337. ADCP refers to antibody-dependent cell-mediated phagocytosis.

An "effector cell" is a leukocyte that expresses one or more constant region receptors and performs an effector function.

A "cytokine" is a protein that is released by one cell and acts as an intercellular mediator on another cell. Cytokines of interest include, but are not limited to, cytokines released from activated T cells such as IL-2, IFNγ and the like.

"Non-immunogenic" refers to a substance in which an immune response does not initiate, induce or enhance an immune response, including adaptive and / or innate immune responses.

The term "isolated" means that a substance is removed from its original environment (eg, the natural environment if naturally occurring). For example, naturally occurring polynucleotides or polypeptides present in living animals are not isolated, but the same polynucleotides or polypeptides isolated from some or all of the coexisting substances in the natural system are isolated. Such polynucleotides can be part of a vector, and / or such polynucleotides or polypeptides can be part of a composition, and such vectors or compositions are in their natural environment. Can still be isolated in that it is not part of.

"Pharmaceutically acceptable excipient" generally means an excipient that is safe, non-toxic and useful in the preparation of the desired pharmaceutical composition and is acceptable for veterinary and human pharmaceutical applications. Contains excipients. Such excipients can be solid, liquid, semi-solid, or gaseous in the case of aerosol compositions.

"Pharmaceutically acceptable salts and esters" means salts and esters that are pharmaceutically acceptable and have the desired pharmacological properties. Such salts include salts that can be formed if the acidic protons present in the compound are capable of reacting with an inorganic or organic base. Suitable inorganic salts include those formed with alkali metals such as sodium and potassium, magnesium, calcium and aluminum. Suitable organic salts include those formed of amine bases such as, for example, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine and the like. Such salts are also inorganic acids (eg, hydrochloric acid and hydrobromic acid) and organic acids (eg, acetic acid, citric acid, maleic acid, and alkane and arene sulfonic acids such as methanesulfonic acid and benzenesulfonic acid). Also included is the acid addition salt formed with. Pharmaceutically acceptable esters include esters formed from the carboxy, sulfonyloxy, and phosphonoxy groups present in the compound, such as the C _1-6 alkyl ester. If two acidic groups are present, the pharmaceutically acceptable salt or ester can be a monoacid monosalt or ester or a disalt or ester, as well if more than two acidic groups are present. Some or all of the groups can be chlorided or esterified. The compounds named in the present invention may be present in non-chloride or non-esterified form, or in chloride and / or esterified form, and the naming of such compounds is the original (non-chloride and non-esterified). ) It is intended to contain both the compound and its pharmaceutically acceptable salts and esters. Also, the particular compounds named in the present invention may be present in two or more racemic forms, and the naming of such compounds is all single stereoisomers of such stereoisomers. And all mixtures (whether racemic or not) are intended to be included.

The terms "pharmaceutically acceptable", "physiologically tolerated" and their grammatical variants are used interchangeably when they refer to compositions, carriers, diluents and reagents. , Represents that the substance can be administered to or on humans without causing undesired physiological effects to the extent that it interferes with the administration of the composition.

The "homology" between two sequences is determined by sequence identity. When two sequences compared to each other have different lengths, sequence identity is preferably associated with the percentage of nucleotide residues in the short sequence that are identical to the nucleotide residues in the longer sequence. Sequence identity is determined by a computer such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8, Unix Computer Group, University Research Park, 575 Science Drive Madison, Wis. 53711). obtain. Bestfit utilizes the local homology algorithm of Smith and Waterman, Applieds in Applied Mathematics 2 (1981), 482-489 to find the segment with the highest sequence identity between the two sequences. When using Bestfit or other sequence alignment programs to determine, for example, whether a particular sequence has 95% identity with the reference sequence of the invention, the parameter is preferably a percentage of identity. Is adjusted to be calculated over the entire length of the reference sequence and to allow a homology gap of up to 5% of the total number of nucleotides in the reference sequence. When using Bestfit, so-called optional parameters are preferably left at their preset (“default”) values. The deviations that appear in the comparison of a given sequence with the above sequences of the invention can be caused, for example, by addition, deletion, substitution, insertion or recombination. Such sequence comparisons are preferably performed in the program "fasta20u66" (Version 2.0u66, September 1998, William R. Pearson and the University of Virginia; WR Pearson (1990), Metzony18). , 63-98, the attached example, and http: //workbench.sdssc.edu/). You may use the "default" parameter setting for this purpose.

A "mutant" is a polypeptide having an amino acid sequence that is somewhat different from that of a naturally occurring polypeptide. Usually, amino acid sequence variants will have at least about 80% sequence identity, more preferably at least about 90% sequence homology. Amino acid sequence variants may have substitutions, deletions, and / or insertions at specific positions within the reference amino acid sequence.

As used herein, the term "vector" is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop to which additional DNA segments can be ligated. Another type of vector is a viral vector and additional DNA segments can be ligated to the viral genome. Certain vectors can replicate autonomously within the host cell into which they are introduced (eg, a bacterial vector having a bacterial origin of replication, and an episomal mammalian vector). Other vectors (eg, non-episomal mammalian vectors) may integrate into the host cell's genome upon introduction into the host cell, thereby replicating with the host genome. In addition, certain vectors can direct the expression of genes to which they are operably linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply "recombinant vectors"). In general, expression vectors useful in recombinant DNA technology are often in the form of plasmids. As used herein, "plasmid" and "vector" can be used interchangeably because plasmid is the most commonly used form of vector.

As used herein, the term "host cell" (or "recombinant host cell") is either genetically modified or genetically modified by the introduction of an exogenous polynucleotide such as a recombinant plasmid or vector. It is intended to refer to cells that can be subjected to. It should be understood that such term is intended to refer not only to a particular cell of interest, but also to the progeny of such cells. Such progeny may not actually be identical to the parent cell, as certain generations may undergo certain modifications due to mutations or environmental influences, but are still used herein. Included in the scope of the term "host cell".

"Binding affinity" is generally the sum of the non-covalent interactions between a single binding site of a molecule (eg, an antibody or other binding molecule) and its binding partner (eg, an antigen or receptor). It refers to the strength of. The affinity of the molecule X for its partner Y can generally be expressed by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Low-affinity antibodies tend to bind weakly to the antigen (or receptor) and dissociate easily, whereas high-affinity antibodies bind the antigen (or receptor) more tightly and remain bound longer. Is.

Unless otherwise stated, the term "conjugate" described and claimed herein is formed by covalent attachment of one or more antibody fragments (s) to one or more polymer molecules (s). Defined as a heterologous molecule, the heterologous molecule is water soluble, i.e. soluble in physiological fluids such as blood, and the heterologous molecule does not contain any structured aggregates. The conjugate of interest is PEG. In the context of the aforementioned definition, the term "structured aggregate" is used to (1) a spheroid or spheroid such that the heterologous molecule is not immobilized on a lipid bilayer, vesicle or liposome rather than a micelle or other emulsion structure. Any aggregates of molecules in aqueous solution with a spheroid shell structure, and (2) aggregates of solid or insolubilized molecules that do not release heterologous molecules into solution upon contact with the aqueous phase, such as (2) chromatobead matrix. That means. Accordingly, the term "conjugate" as defined herein refers to the above in precipitates, sediments, biodegradable matrices or other solids capable of releasing heterologous molecules into an aqueous solution upon hydration of the solid. Includes heterologous molecules.

As used herein, the term "label" refers to a detectable compound or composition that is directly or indirectly conjugated to an antibody. The label may be detectable on its own (eg, a radioisotope label or a fluorescent label), or in the case of an enzyme label, it may catalyze a detectable substrate compound or chemical change in the composition.

By "solid phase" is meant a non-aqueous matrix to which the antibodies of the invention can adhere. Examples of solid phases included herein include glass (eg, controlled pore glass), polysaccharides (eg, agarose), polyacrylamide, polystyrene, polyvinyl alcohol, and some or all of the silicone. Includes what is formed. In certain embodiments, depending on the circumstances, the solid phase may constitute a well of the assay plate, in which it is a purification column (eg, an affinity chromatography column). The term also includes discontinuous solid phases of individual particles, such as those described in US Pat. No. 4,275,149.

Antibodies, also referred to as immunoglobulins, usually include at least one heavy chain and one light chain, and the amino terminal domains of the heavy and light chains are variable in sequence and are therefore generally variable region domains, or variable heavy chains ( VH) domain or variable light chain (VH) domain. The two domains customarily associate to form a specific binding region, but as discussed herein, specific binding can also be obtained with heavy chain-only variable sequences and various non-antibodies. Natural three-dimensional arrangements are known and are used in the art.

"Functional" or "biologically active" antibodies or antigen-binding molecules, including heavy chain-only antibodies and bispecific triple-chain antibody-like molecules (TCA) herein, are structural. It is capable of exerting one or more of its natural activities in regulatory, biochemical or biophysical events. For example, a functional antibody or other binding molecule, such as TCA, may have the ability to specifically bind to an antigen, and binding induces or modifies cellular or molecular events such as signal transduction or enzymatic activity. obtain. Functional antibodies or other binding molecules, such as TCA, can also block ligand activation of the receptor or act as an agonist or antagonist. To exert one or more of its natural activity, the ability of an antibody or other binding molecule, such as TCA, depends on several factors, including proper folding and assembly of the polypeptide chain.

The term "antibody" as used herein is used in the broadest sense, and specifically, a monoclonal antibody, a polyclonal antibody, a monomer, a dimer, a multimer, and a multispecific antibody (for example, bispecificity). (Antibodies), heavy chain only antibodies, triple chain antibodies, single chain Fv, nanobodies, etc., and as long as they exhibit the desired biological activity, include antibody fragments (Miller et al (2003) Jour. . Of Immunology 170: 4854-4861). Antibodies may be of mouse, human, humanized, chimeric, or other species origin.

The term antibody may refer to a polypeptide comprising a full-length heavy chain, a full-length light chain, an intact immunoglobulin molecule, or an antigen-binding site that immunospecifically binds to or a portion of an antigen of interest of interest. Targets include, but are not limited to, cancer cells, or cells that produce autoimmune antibodies associated with autoimmune diseases. The immunoglobulins disclosed herein include any type (eg, IgG, IgE, IgM, IgD, and IgA), including manipulation subclasses with modified Fc moieties that provide reduced or enhanced effector cell activity. ), Class (eg, IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or a subclass of immunoglobulin molecule. Immunoglobulins can be derived from any species. In one embodiment, the immunoglobulin is largely of human origin.

The term "variable" refers to the fact that certain parts of a variable domain differ greatly in the sequences between antibodies and are used in the binding and specificity of each particular antibody to that particular antigen. However, the variability is not evenly distributed throughout the variable domain of the antibody. It is concentrated in three segments called hypervariable regions of both the light chain variable domain and the heavy chain variable domain. The more highly conserved portion of the variable domain is called the framework region (FR). The variable domains of the natural heavy and light chains each form a beta-sheet structure linked by three hypervariable regions that form a loop connecting the beta-sheet structures, and in some cases form part of the beta-sheet structure. Includes four FRs that are mainly used. The hypervariable regions in each strand are closely held together by FR and contribute to the formation of the antigen binding site of the antibody by the hypervariable regions derived from the other strand (Kabat et al (1991) Sequences of Proteins of Immunological). See Interest, 5th Ed. Public Health Service, National Antibodies of Health, Bethesda, Md.). The constant domain is not directly involved in antibody binding to the antigen, but exhibits various effector functions such as antibody involvement in antibody-dependent cellular cytotoxicity (ADCC).

The term "hypervariable region" as used herein refers to an amino acid residue of an antibody involved in antigen binding. The hypervariable regions may include amino acid residues from the "complementarity determining regions" or "CDRs" and / or these residues from the "hypervariable loops". A "framework region" or "FR" residue is a variable domain residue other than the hypervariable region residues defined herein.

The variable region of interest comprises at least one CDR sequence from the family 2 variable region provided herein, usually at least two CDR sequences, more usually three CDR sequences. Although exemplary CDR designations are set forth herein, one of ordinary skill in the art will appreciate that many definitions of CDRs, including the definition of Kabat, are commonly used (“Zhao et al. A germline knowledge based). Computational approach for decoding antibody. "Mol Immunol. 2010; 47: 694-700), which is based on sequence variability and is most commonly used. The definition of Chothia is based on the location of the structural loop region (Chothia et al. "Conformations of antibody variable regions." Nature. 1989; 342: 877-883). The definition of a CDR for another purpose is, but is not limited to, Honegger, “Yet another number scheme for antibody domain: an automatic modeling; et al. "Automated identification of complementarity determining regions (CDRs) reveals peculiar characteristics of CDRs and B cell epitopes." J Immunol 2008; 181:. 6230-6235; Almagro "Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: specificities for the rational design of antibody repertoires. ”J Mol Recognition. 2004; 17: 132-143; and Padranet al. "Identification of specificity-determining reactions in antibodies." Including those disclosed by Faceb J. 1995; 9: 133-139., Each of which is specifically incorporated herein by reference.

As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., individual antibodies comprising the population may be present in small amounts. It is identical except for some natural mutations. Monoclonal antibodies are highly specific and are directed against a single antigenic site. Moreover, in contrast to polyclonal antibody preparations that contain different antibodies to different determinants (epitope), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, monoclonal antibodies are advantageous in that they can be synthesized without being contaminated by other antibodies. The modifier "monoclonal" indicates the properties of an antibody obtained from a substantially homogeneous population of antibodies and should not be construed as requiring the production of the antibody by any particular method.

The antibodies herein are specifically such that the heavy and / or part of the light chain is identical or homologous to the corresponding sequence of an antibody derived from a particular species or an antibody belonging to a particular antibody class or subclass. The remainder of the chain (s) is an antibody derived from another species, or an antibody belonging to another antibody class or subclass, and so on, as long as it exhibits the desired biological activity. Identical or homologous to the sequence corresponding to the fragment of the antibody (US Pat. No. 4,816,567, and Morrison et al (1984) Proc. Natl. Acad. Sci. USA, 81: 6851-6855). Chimeric antibodies of interest herein include variable domain antigen binding sequences from non-human primates (eg, Old World monkeys, apes, etc.), as well as "primated" antibodies comprising human constant region sequences.

As used herein, an "intact antibody chain" includes a full-length variable region and a full-length constant region (Fc). Intact "conventional" antibodies include intact light chains and intact heavy chains, as well as light chain constant domains (CL) and heavy chain constant domains CH1, hinges, CH2 and CH3 for secretory IgG. Other isotypes such as IgM or IgA may have different CH domains. The constant domain may be a constant domain of a natural sequence (eg, a constant domain of a human natural sequence) or an amino acid sequence variant thereof. An intact antibody may have one or more "effector functions" meaning biological activity due to the Fc constant region of the antibody (natural sequence Fc region or amino acid sequence mutant Fc region). Examples of antibody effector functions include C1q binding, complement-dependent cellular cytotoxicity, Fc receptor binding, antibody-dependent cellular cytotoxicity (ADCC), feeding, and cell surface receptor downregulation. Is done. Mutants in the constant region include those that alter the effector profile, binding to Fc receptors, and the like.

Depending on the amino acid sequence of their heavy chain Fc (constant domain), antibodies and various antigen-binding proteins can be provided as different "classes". There are five major classes of heavy chain Fc regions: IgA, IgD, IgE, IgG, and IgM, some of which are further "subclasses" (isotypes) such as IgG1, IgG2, IgG3, IgG4, IgA, And can be classified as IgA2. The Fc constant domains corresponding to different classes of antibodies are called α, δ, ε, γ and μ, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known. Ig forms include hinge-modified or hingeless forms (Roux et al (1998) J. Immunol. 161: 4083-4090; Lund et al (2000) Eur. J. Biochem. 267: 7246-7256; US2005 / 0048572. 2004/0229310). The light chains of antibodies from any vertebrate species can be assigned to one of two types, called κ and λ, based on the amino acid sequences of their constant domains.

The "functional Fc region" has the "effector function" of the Fc region of the native sequence. Exemplary effector functions include C1q binding, CDC, Fc receptor binding, ADCC, ADCP, downregulation of cell surface receptors (eg, B cell receptors) and the like. Such effector functions generally require the Fc region to interact with receptors such as FcγRI, FcγRIIA, FcγRIIB1, FcγRIIB2, FcγRIIIA, FcγRIIIB receptors, and low affinity FcRn receptors, eg, the present. It can be evaluated using various assays as disclosed in the definition of the specification. A "dead" Fc is one that has been mutated to retain activity, for example with respect to prolonged serum half-life, but does not activate high affinity Fc receptors.

The "Natural sequence Fc region" includes an amino acid sequence identical to the amino acid sequence of a naturally found Fc region. The human Fc region of the natural sequence includes, for example, the human IgG1 Fc region of the natural sequence (non-A and A allotypes), the human IgG2 Fc region of the natural sequence, the human IgG3 Fc region of the natural sequence, and the human IgG4 Fc region of the natural sequence. , As well as those naturally occurring variants.

The "variant Fc region" comprises an amino acid sequence that differs from the amino acid sequence of the Fc region of the natural sequence by at least one amino acid modification, preferably one or more amino acid substitutions (s). Preferably, the variant Fc region is about one amino acid substitution compared to the Fc region of the native sequence, or the Fc region of the parent polypeptide, eg, the Fc region of the native sequence or the Fc region of the parent polypeptide. It has 1 to about 10 amino acid substitutions, preferably about 1 to about 5 amino acid substitutions. The variant Fc region herein is preferably at least about 80% homology, most preferably at least about 90% homology to the Fc region of the native sequence and / or the Fc region of the parent polypeptide. More preferably, it has at least about 95% homology with it.

Three mutant Fc sequences in the CH2 region to reduce FcγRI binding at positions 234, 235, and 237 of the EU index (see Duncan et al., (1988) Nature 332: 563). May include amino acid substitutions in. Two amino acid substitutions at the complement C1q binding site at EU indexes 330 and 331 reduce complement fixation (Tao et al., J. Exp. Med. 178: 661 (1993), and Canfield and Morrison. , J. Exp. Med. 173: 1483 (1991)). Substitution of IgG2 residues at positions 233-236 and IgG4 residues at positions 327, 330 and 331 with human IgG1 significantly reduces ADCC and CDC (eg, Armour KL. Et al., 1999 Eur J. Immunol. 29 (8): 2613-24; and Sheets RL. Et al., 2001. J Biol Chem. 276 (9): 6591-604). Other Fc variants are possible, but not limited to, those lacking regions capable of forming disulfide bonds, or specific amino acid residues at the N-terminus of the natural Fc form. Includes those that have been removed with or have methionine residues added to it. Thus, in one embodiment of the invention, one or more Fc moieties of the ScFc molecule may contain one or more mutations in the hinge region to eliminate disulfide bonds. In yet another embodiment, the hinge region of the Fc can be completely removed. In yet another embodiment, the molecule may comprise an Fc variant.

In addition, Fc variants can be constructed to eliminate or substantially reduce effector function by substituting, deleting or adding amino acid residues for complement or Fc receptor binding. For example, but not limited to, deletions can occur in complement binding sites such as the C1q binding site. Techniques for preparing such sequence derivatives of immunoglobulin Fc fragments are disclosed in International Patent Publications WO97 / 34631 and WO96 / 32478. In addition, the Fc domain can be modified by phosphorylation, sulfation, acylation, glycosylation, methylation, farnesylation, acetylation, amidation and the like.

Fc may be in the form of a natural sugar chain, an increased sugar chain compared to the natural type, or a decreased sugar chain compared to the natural type, or in a non-glycosylated or deglycosylated form. There may be. Increase, decrease, removal or other modification of sugar chains is achieved by methods common in the art such as chemical, enzymatic methods, or by expressing it in genetically engineered production cell lines. obtain. Such cell lines can include microorganisms that naturally express glycosylation enzymes (eg, Pichia Pastoris), and mammalian cell lines (eg, CHO cells). In addition, the microorganism or cell can be engineered to express glycosylation enzymes or prevent glycosylation enzymes from being expressed (eg, Hamilton, et al., Science, 313: 1441 (2006); Kanda, et al, J. Biotechnology, 130: 300 (2007); Kitagawa, et al., J. Biol. Chem., 269 (27): 17872 (1994); Ujita-Lee et al., J. Biol. Chem. , 264 (23): 13848 (1989); Imai-Nishiya, et al, BMC Biotechnology 7:84 (2007); and WO 07/055916). As an example of cells engineered to alter sialylation activity, the alpha-2,6-sialylltransferase 1 gene has been engineered into Chinese hamster ovary cells and sf9 cells. Therefore, the antibodies expressed by these engineered cells are sialylated by the exogenous gene product. A further method for obtaining Fc molecules with modified amounts of sugar residues compared to multiple natural molecules is, for example, using lectin affinity chromatography to glycosylate and non-glycosylate the plurality of molecules. Includes fractional separation (see, eg, WO07 / 117505). The presence of specific glycosylation moieties has been shown to alter the function of immunoglobulins. For example, removal of sugar chains from the Fc molecule results in a sharp decrease in binding affinity for the C1q portion of the first complement component C1 and antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cells. It results in a reduction or loss of injuries (CDC), thereby not inducing an unwanted immune response in vivo. Further important modifications include sialylation and fucosylation, where the presence of sialic acid in IgG correlates with anti-inflammatory activity (see, eg, Kaneko, et al, Science 313: 760 (2006)). However, removal of fucose from IgG leads to enhanced ADCC activity (see, eg, Shoj-Hosaka, et al, J. Biochem., 140: 777 (2006)).

In an alternative embodiment, the antibodies of the invention may have Fc sequences with enhanced effector function, for example by enhancing binding ability to FcγRIIIA and enhancing ADCC activity. For example, fucose bound to N-linked glycans at Asn-297 of Fc sterically interferes with the interaction of Fc with FcγRIIIA, and removal of fucose by sugar manipulation can increase binding to FcγRIIIA. , It bridges with ADCC activity> 50-fold higher compared to wild-type IgG1 controls. Protein engineering has generated multiple variants that increase the affinity of Fc binding to FcγRIIIA via amino acid mutations in the Fc portion of IgG1. In particular, the triple alanine variants S298A / E333A / K334A show 2-fold increased binding to FcγRIIIA and ADCC function. The S239D / I332E (2x) and S239D / I332E / A330L (3x) mutants have a marked increase in binding affinity for FcγRIIIA and an increase in ADCC capacity in vitro and in vivo. Other Fc variants identified by yeast display also showed improved binding to FcγRIIIA and enhanced tumor cell killing in mouse xenograft models. See, for example, Liu et al. (2014) JBC 289 (6): 3571-90, which is specifically incorporated herein by reference.

The term "antibody containing an Fc region" refers to an antibody containing an Fc region. The C-terminal lysine of the Fc region (residue 447 by the EU numbering system) can be removed, for example, during antibody purification or by recombinant manipulation of the nucleic acid encoding the antibody. Thus, an antibody with an Fc region according to the invention may comprise an antibody with or without K447.

"Fv" is a minimal antibody fragment containing complete antigen recognition and antigen binding sites. The CD3-binding antibody of the invention contains a dimer of one heavy chain variable domain and one light chain variable domain in a tight and non-covalent manner, but for use with additional antibodies such as multispecific configurations. Therefore, VH may be included in the absence of the VL sequence. The affinity may be lower than the affinity of the two domain binding sites, but it also recognizes the antigen in a single variable domain (or half of the Fv containing only three antigen-specific hypervariable regions). Has the ability to bind.

The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. The Fab'fragment differs from the Fab fragment in that it adds a small number of residues to the carboxy terminus of the heavy chain CH1 domain containing one or more cysteines from the antibody hinge region. Fab'-SH is the name herein for Fab'where the constant domain cysteine residue (s) have at least one free thiol group. The F (ab') ₂ antibody fragment was originally produced as a pair of Fab' fragments with hinge cysteine between them. Other chemical couplings of antibody fragments are also known.

The "humanized" form of a non-human (eg, rodent) antibody containing a single-chain antibody is a chimeric antibody (including a single-chain antibody) containing the smallest sequence derived from a non-human immunoglobulin. For example, Jones et al, (1986) Nature 321: 522-525; Chocolate et al (1989) Nature 342: 877; Richmann et al (1992) J. Mol. Biol. 224, 487-499; Foote and Winter. 1992) J. Mol. Biol. 224: 487-499; Presta et al (1993) J. Immunol. 151, 2623-2632; Werther et al (1996) J. Immunol. Methods 157: 4986-4995; and Presta. See al (2001) Thromb. Naturest. 85: 379-389. For more details, see US Pat. Nos. 5,225,539, 6,548,640, 6,982,321, 5,585,089, 5,693,761, 6,6. See 407, 213, Jones et al (1986) Nature, 321: 522-525; and Richmann et al (1988) Nature 332: 323-329.

As used herein, the term "single-chain antibody" means a single polypeptide chain that contains one or more antigen-binding domains that bind to an epitope of an antigen, such domain being an antibody heavy chain. Or it is derived from or has sequence identity with the variable region of the light chain. Some of such variable regions can be encoded by the _VH or _VL gene segment, the D and _JH gene segments, or the _JL gene segment. The variable region can be encoded by a rearranged V _H DJ _H , V _L DJ _H , V _H J _L , or V _L J _L gene segment. The V-, D-, and J-gene segments can be derived from humans and various animals including birds, fish, sharks, mammals, rodents, non-human primates, camels, llamas, rabbits, and the like.

The CD3-binding antibody of the present invention has been found to be particularly useful in multispecific configurations including, but not limited to, bispecific antibodies, trifunctional antibodies and the like. A wide variety of methods and protein configurations are known and are used in bispecific monoclonal antibodies (BsMABs), trispecific antibodies and the like.

First generation BsMAbs consisted of two heavy chains and two light chains, one from each of two different antibodies. The two Fab regions are directed against the two antigens. The Fc region is composed of two heavy chains and forms a third binding site with Fc receptors on immune cells (eg, Lindhofer et al., The Journal of Immunology, Vol 155, p219-225, 1995). Please refer to). Antibodies may be of the same or different species. For example, cell lines expressing rat and mouse antibodies secrete functional bispecific Abs due to preferentially species-restricted heavy and light chain pairing. In other embodiments, the Fc regions are designed only to fit together in a particular way.

Other types of bispecific antibodies include chemically linked Fabs consisting only of Fab regions. Two chemically linked Fabs or Fab2 fragments form artificial antibodies that bind to two different antigens, making this a type of bispecific antibody. Antigen-binding fragments (Fab or Fab2) of two different monoclonal antibodies are produced and linked by chemical means such as thioether (Glennie, MJ et al., Journal of immunology 139, p 2376-75, 1987; see Peter Borchmann et al., Blood, Vol. 100, No. 9, p3101-3107, 2002).

Various other methods for the production of multivalent artificial antibodies have been developed by recombinant fusion of the variable domains of the two antibodies. Single-chain variable fragments (scFv) are fusion proteins of the variable regions of the heavy and light chains (VH) and light chains (VL) of immunoglobulins, linked to short linker peptides of 10 to about 25 amino acids. Linkers are usually rich in glycine for flexibility and serine or threonine for solubility and can bind the N-terminus of VH to the C-terminus of VL and vice versa. .. Bispecific single-chain variable fragments (di-scFv, bi-scFv) can be engineered by linking two scFvs with different specificities. A single peptide chain with two VHs and two VL regions is produced, resulting in a divalent scFv.

The bispecific tandem scFv is also known as a bispecific T cell engage (BiTE). Bispecific scFv can be made using a linker peptide that forces the scFv to dimerize, where the two variable regions are too short to fold together (about 5 amino acids). This type is known as diabody (Adams et al., British journal of cancer 77, p1405-12, 1998). Dual-Affinity Re-Trading (DART) platform technology (Macrogenics, Rockville, Md). This fusion protein technique uses two single chain variable fragments (scFv) of different antibodies on a single peptide chain of about 55 kilodaltons. SCORPION Therapeutics (Emergent BioSolutions, Inc., Seattle, Wash.) Combines two antigen-binding domains in a single-stranded protein. Based on the immunoglobulin Fc region, one binding domain is at the C-terminus and the second binding domain is at the N-terminus of the effector domain.

Tetravalent and bispecific antibody-like proteins also include DVD-Igs engineered from two monoclonal antibodies (Wu, C. et al., Nature Biotechnology, 25, p1290-1297, 2007). To construct the DVD-Ig molecule, the V domains of the two mAbs were fused in tandem with the variable domain of the N-terminal first antibody light (VL) chain by a short linker (TVAAP), followed by the other. The antibodies VL and Ck are followed to form the DVD-Ig protein light chain. Similarly, the variable regions of the heavy (VH) chains of the two mAbs are fused in tandem with the N-terminal first antibody by a short linker (ASTKGP), followed by fusion of the other antibody and the heavy chain constant domain. To form a DVD-Ig protein heavy chain (VH1 / VL1). All light and heavy chain constant domains are conserved in the DVD-Ig design because they are important for the formation of disulfide-bonded complete IgG-like molecules. Co-transfection of mammalian cells with expression vectors encoding DVD-Ig light and heavy chains results in the secretion of a single species of IgG-like molecule with a molecular weight of approximately 200 kDa. This molecule has two four binding sites from each mAb.

The term "bispecific triple chain antibody-like molecule" or "TCA" is used herein to refer to an antibody-like molecule comprising, essentially, or consisting of three polypeptide subunits. Two of which contain an antigen-binding region and at least one CH domain, one heavy chain and one light chain of a monoclonal antibody, or a functional antigen-binding fragment of such an antibody chain. Become or consist of them in essence. This heavy / light chain pair has binding specificity for the first antigen. The third polypeptide subunit is a heavy chain-only antibody containing an Fc moiety containing the CH2 and / or CH3 and / or CH4 domain in the absence of the CH1 domain and an epitope of the second antigen or the first. Includes, consists of, or consists of antigen-binding domains that bind to different epitopes of the antigen, such binding domains are derived from or sequence identity with the variable regions of the antibody heavy or light chain. Have. Some of such variable regions can be encoded by the _VH and / or _VL gene segment, the D and _JH gene segments, or the _JL gene segment. The variable region can be encoded by a rearranged V _H DJ _H , V _L DJ _H , V _H J _L , or V _L J _L gene segment.

As used herein, "TCA protein utilizes heavy chain only antibodies" or "heavy chain antibodies" or "heavy chain polypeptides" are heavy chain constant regions CH2 and / or CH3 domains and /. Alternatively, it means a single-chain antibody containing a CH4 domain but not a CH1 domain. In one embodiment, the heavy chain antibody consists of an antigen binding domain, at least part of the hinge region and CH2 and CH3 domains. In another embodiment, the heavy chain antibody consists of an antigen binding domain, at least a portion of the hinge region and a CH2 domain. In a further embodiment, the heavy chain antibody consists of an antigen binding domain, at least a portion of the hinge region and a CH3 domain. Heavy chain antibodies in which the CH2 and / or CH3 domains have been cleaved are also included herein. In a further embodiment, the heavy chain consists of an antigen binding domain and at least one CH (CH1, CH2, CH3 or CH4) domain, but does not include a hinge region. Heavy chain-only antibodies may have two heavy chains disulfide-bonded, or may be in the form of dimers covalently or non-covalently bound to each other. Heavy chain antibodies may belong to the IgG subclass, but antibodies belonging to other subclasses such as IgM, IgA, IgD and IgE subclasses are also included herein. In certain embodiments, the heavy chain antibody is an IgG1, IgG2, IgG3, or IgG4 subtype, in particular the IgG1 subtype.

Heavy chain antibodies make up about a quarter of the IgG antibodies produced by camelids, such as camels and llamas (Hamers-Casterman C., et al. Nature. 363, 446-448 (1993)). .. These antibodies are formed by two heavy chains but lack a light chain. As a result, the variable antigen binding moiety is referred to as the VHH domain, which represents the smallest naturally occurring intact antigen binding site with only about 120 amino acids in length (Desmyter, A., et al. J. Biol). Chem. 276, 26285-26290 (2001)). Heavy chain antibodies with high specificity and affinity can be produced against a variety of antigens by immunization (van der Linden, R.H., et al. Biochim. Biophys. Acta. 1431, 37-46 ( 1999)), the VHH moiety can be easily cloned and expressed in yeast (Frenken, L.G.J., et al. J. Biotechnol. 78, 11-21 (2000)). Their expression levels, solubility and stability are significantly higher than those of classical F (ab) or Fv fragments (Ghahrouudi, MA et al. FEBS Lett. 414, 521-526 (1997)). .. Sharks have also been shown to have a single VH-like domain in the antibody VNAR (Nuttall et al. Eur. J. Biochem. 270, 3543-3554 (2003); Nuttall et al. Function and Bioinformatics 55. , 187-197 (2004); Domaine et al., Molecular Immunology 40, 25-33 (2003)).

An antibody or antigen-binding molecule comprising a heavy chain-only antibody and a bispecific triple-stranded antibody-like molecule (TCA) as used herein "binds" to the antigen of interest, but binds to the antigen with sufficient affinity. Such antibodies or binding molecules are useful as diagnostic and / or therapeutic agents in targeting antigens and do not significantly cross-react with other proteins. In such embodiments, the degree of binding of the antibody or other binding molecule to the non-target antigen is less than 10% as determined by fluorescence activated cell selection (FACS) analysis or radioimmunoprecipitation (RIA). be.

Proteins The present invention provides a family of closely related antibodies that bind to CD3 and activate signal transduction via CD3 (eg, activation of CD3 ⁺ T cells). Antibodies within the family include the set of CDR sequences defined herein and are exemplified by the provided VH sequences of SEQ ID NOs: 1-18. The family of antibodies provides many benefits that contribute to its usefulness as a clinical therapeutic agent (s). Antibodies within the family include members with a range of binding affinities, allowing selection of specific sequences with the desired affinities. The ability to fine-tune affinity is of particular importance to control the level of CD3 activation in the individual being treated, thereby reducing toxicity. For example, if small and abundant tumor antigens (less than 10,000 molecules per cell) are targeted, high affinity CD3 binders (<30 nM) are expected to be preferred. If very abundant tumor antigens (more than 50,000 molecules per cell) are targeted, CD3 conjugates with low affinity (> 50 nM) are preferred. Aside from affinity, antibodies that induce cytokine release when bound to T cells, such as IL-2, IFNγ, etc., when reduced cytokine release is desired. It can be a trend.

Suitable antibodies include, but are not limited to, use as bispecific antibodies and can be selected from those provided herein for development and use. Determination of affinity for a candidate protein can be performed using methods known in the art, such as viacore measurements. Members of the antibody family may have an affinity for CD3 at Kd of about ^10-6 to about ^10-11 and, but are not limited to, about ^10-6 to about ^10-10 , about ^10-6 to. About ^10-9 , about ^10-6 to about ^10-8 , about ^10-8 to about ^10-11 , about ^10-8 to about ^{10-10, about 10-8 to about 10-9 , about 10-9} to Includes about ^10-11 , about ^10-9 to about ^10-10 , or any value within these ranges. Affinity selection can be confirmed, for example, using biological assessments for T cell activation, and potential toxicity assessments in vitro or in preclinical models. Determination of cytokine release can be evaluated using any convenient method, including, but not limited to, the assays described in the Examples.

Engagement of the T cell receptor (TCR) by binding the MH peptide complex or anti-TCR / CD3 antibody initiates T cell activation. Examples of anti-TCR / CD3 antibodies that activate T cells are OKT3 and UCHT1. These anti-CD3 antibodies cross-competition for binding to CD3 on T cells and are routinely used in T cell activation assays. The anti-CD3 antibody of the present invention cross-competites with OKT3 for binding to human CD3. Depending on the binding affinity for CD3 and epitopes on CD3, anti-CD3 antibodies activated T cells with different functional results. In vitro in vitro incubation of human T cells with low affinity anti-CD3 antibodies resulted in incomplete activation of T cells and low IL-2 and IL-10 production. In contrast, high affinity CD3 binders activated T cells to produce significantly more IL-2 and other cytokines. Low affinity anti-CD3 antibodies selectively induce some effector functions, potent tumor killing and upregulation of CD69, while others such as IL-2 and IL-10 production. It is considered to be a partial agonist that does not induce. The high affinity binder of the present invention is a complete agonist that activates many immune effector functions of T cells. The strength of the interaction between CD3 and the recognized epitope resulted in qualitatively different activation of T cells. The production of maximal cytokines in T cells activated by the low affinity anti-CD3 antibody was lower than the maximal activation by the high affinity anti-CD3 antibody. In some embodiments, the antibodies of the invention are more than one or both of IL-2 and IL-10 when compared to the reference anti-CD3 antibody in the same assay and when combined with T cells in the activation assay. With low release, the reference antibody can be ID304703 (SEQ ID NO: 22), or an antibody of equivalent affinity. The maximum release of IL-2 and / or IL-10 can be less than about 75% of the release by the reference antibody, less than about 50% of the release by the reference antibody, and less than about 25% of the release by the reference antibody. It is possible that it is less than about 10% of the release by the reference antibody.

In some embodiments of the invention bispecific or multispecific antibodies are provided, which may have, but are not limited to, any of the configurations discussed herein. , Includes triple-stranded bispecificity. Bispecific antibodies include at least heavy chain variable regions of antibodies specific for proteins other than CD3, and may include heavy chain and light chain variable regions. In some such embodiments, the second antibody specificity binds to a tumor-related antigen, such as a target antigen such as an integrin, a pathogen antigen, a checkpoint protein, and the like. Various forms of bispecific antibodies, including, but not limited to, single-stranded polypeptides, double-stranded polypeptides, triple-stranded polypeptides, quadruplex polypeptides, and multiples thereof. It is within the scope of the present invention.

A family of CD3-specific antibodies comprises the VH domain comprising the CDR1, CDR2 and CDR3 sequences in the human VH framework. The CDR sequences, as an example, are approximately amino acid residues 26-33, 51-58 and 97-112 for CDR1, CDR2 and CDR3 of the exemplary variable region sequences provided in SEQ ID NOs: 1-18, respectively. Can be located in the area. It will be appreciated by those skilled in the art that if different framework sequences are selected, the CDR sequences can be in different positions, but the order of the sequences generally remains the same.

ここで、Ｘ_５は、任意のアミノ酸であってもよく、いくつかの実施形態において、Ｘ_５は、Ｄ、ＡまたはＨであり、いくつかの実施形態において、Ｘ_５は、Ｄである。Ｘ_６は、任意のアミノ酸であってもよく、いくつかの実施形態において、Ｘ_６は、ＤまたはＮであり、いくつかの実施形態において、Ｄ_６は、Ｄである。いくつかの実施形態において、ファミリー２の抗ＣＤ３抗体のＣＤＲ１配列は、配列番号１～１８、残基２６～３３のいずれかに記載の配列を含む。 The CDR sequence of a Family 2 antibody may have the following sequence formula: X represents a variable amino acid and may be a specific amino acid as shown below.

Here, X ₅ may be any amino acid, in some embodiments X ₅ is D, A or H, and in some embodiments X ₅ is D. X ₆ may be any amino acid, in some embodiments X ₆ is D or N, and in some embodiments D ₆ is D. In some embodiments, the CDR1 sequence of a Family 2 anti-CD3 antibody comprises the sequence set forth in any of SEQ ID NOs: 1-18, residues 26-33.

いくつかの実施形態において、ファミリー２の抗ＣＤ３抗体のＣＤＲ２配列は、配列番号１～１８、残基５１～５８のいずれかに記載の配列を含む。

In some embodiments, the CDR2 sequence of a Family 2 anti-CD3 antibody comprises the sequence set forth in any of SEQ ID NOs: 1-18, residues 51-58.

ここで、
Ｘ_９’は、任意のアミノ酸であってもよく、いくつかの実施形態において、Ｘ_９’は、ＤまたはＳであり、いくつかの実施形態において、Ｘ_９’は、Ｄであり、
Ｘ_１１’は、任意のアミノ酸であってもよく、いくつかの実施形態において、Ｘ_１１’は、ＲまたはＳであり、
Ｘ１２’は、任意のアミノ酸であってもよく、いくつかの実施形態において、Ｘ_１２’は、ＬまたはＲである。

here,
X _9'may be any amino acid, in some embodiments X _9'is D or S, and in some embodiments X _9'is D.
X _11'may be any amino acid, and in some embodiments, X _11'is R or S.
X12'may be any amino acid, and in some embodiments, _X12'is L or R.

を有し、Ｘ_１１’及びＸ_１２’は、上記で定義されている。いくつかの実施形態において、ファミリー２の抗ＣＤ３抗体のＣＤＲ３配列は、配列番号１～１８、残基９７～１１２のいずれかに記載の配列を含む。 In some embodiments, the CDR3 sequence of the family 2 anti-CD3 antibody is the formula:

And X 11'and X _{12' are} defined above. In some embodiments, the CDR3 sequence of a Family 2 anti-CD3 antibody comprises the sequence set forth in any of SEQ ID NOs: 1-18, residues 97-112.

In some embodiments, the CD3-bound VH domain is paired with the light chain variable region domain. In some such embodiments, the light chain is a fixed light chain. In some embodiments, the light chain comprises a VL domain having CDR1, CDR2 and CDR3 sequences in the human VL framework. The CDR sequence may be one contained in SEQ ID NO: 19. In some embodiments, the CDR1 sequence comprises amino acid residues 27-32, 50-52, 89-97 for CDR1, CDR2, CDR3, respectively.

In some embodiments, the CDR sequences of the antibodies of Family 2 are at least 85% identity, at least 90%, to the set of CDR sequences or CDR sequences set forth in any one of SEQ ID NOs: 1-18. Have a sequence having at least 95% identity, at least 99% identity. In some embodiments, the CDR sequences of the invention are substituted with one, two, three or more amino acids for any one of the CDR sequences of SEQ ID NOs: 1-18 or a set of CDR sequences. include. In some embodiments, the amino acid substitutions (s) are 5- or 10-positions of CDR1, 2-positions, 6- or 7-positions of CDR2, 1-positions, 8-positions, 9-positions of CDR3 with respect to the above formula. One or more of the ranks or tens.

When the proteins of the invention are bispecific antibodies, only one binding moiety, the VH / VL combination or VH, is specific for human CD3, while the other arm is ovarian cancer, breast cancer, gastrointestinal. Target cells, including cancer cells such as tubes, brain tumors, head and neck cancers, prostate cancers, colon cancers, and lung cancers, as well as leukemia, lymphoma, sarcoma, cancer tumors, nerve cell tumors, squamous cell carcinoma, embryos. Like cell tumors, metastases, undifferentiated tumors, sperm epithelioma, melanoma, myeloma, neuroblastoma, mixed cell tumors, and neoplasm formation by infectious factors, and B-cell tumors including other malignancies. It can be specific for hematological malignancies, pathogen-infected cells, and autoreactive cells that cause inflammation and / or autoimmunity. The non-CD3 portion can also be specific for immunomodulatory proteins, as described herein.

Tumor-related antigens (TAAs) are relatively limited to tumor cells, whereas tumor-specific antigens (TSAs) are unique to tumor cells. TSA and TAA are typically parts of the intracellular molecule expressed on the cell surface as part of the major histocompatibility complex.

Tissue-specific differentiation antigens are molecules present on the counterparts of tumor cells and their normal cells. Tumor-related antigens known to be recognized by therapeutic mAbs fall into several different categories. Hematopoietic differentiation antigens are usually glycoproteins associated with the differentiation (CD) classification group, including CD20, CD30, CD33 and CD52. Cellular surface differentiation antigens are a diverse group of glycoproteins and carbohydrates found on the surface of both normal and tumor cells. Antigens involved in proliferation and differentiation signaling are often growth factors and growth factor receptors. Growth factors targeted by antibodies in cancer patients include CEA, epidermal growth factor receptor (EGFR, also known as ERBB1), ERBB2 (also known as HER2), ERBB3, MET (HGFR). Also known as), insulin-like growth factor 1 receptor (IGF1R), effrin receptor A3 (EPHA3), tumor necrosis factor (TNF) -related apoptosis-inducing ligand receptor 1 (TRAILR1, TNFRSF10A). ), TRAILR2 (also known as TNFRSF10B) and receptor activator of nuclear factor κB ligand (RANKL, also known as TNFSF11). The antigens involved in angiogenesis are usually proteins or growth factors that support the formation of new microvasculature, including vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR), integrin αVβ3 and integrin α5β1. Tumor stroma and extracellular matrix are essential supporting structures for tumors. Stroma and extracellular matrix antigens that are therapeutic targets include fibroblast-activating proteins (FAPs) and tenascin.

Examples of therapeutic antibodies useful in bispecific configurations include, but are not limited to, rituximab, ibritsumomab, chiuximab, toshitumomab, brentuximab, vedotin, gemtuzumab, ozogamycin, alemtuzumab, IGN101, adecatumumab, and labetuximab. , HuA33, pemtuzumab, olegobomab, CC49 (minretsumomab), cG250, J591, MOv18, MORAb-003 (faretsuzumab), 3F8, ch14.18, KW-2871, hu3S193, IgN311, bebashizumab, IM-2C6 , Cetuximab, Panitumumab, Nimotuzumab, 806, Trastuzumab, Pertuzumab, MM-121, AMG102, METMAB, SCH900105, AVE1642, IMC-A12, MK-0646, R1507, CP 751871, KB004, IIIA4, Mapatsum -ETR2, CS-1008, denosumab, cetuximab, F19, and 81C6.

Most in the context of clinical cancer immunotherapy, cytotoxic T lymphocyte-related antigen 4 (also known as CTLA4, CD152) and programmed cell death protein 1 (also known as PD1, CD279). Both actively studied immune checkpoint receptors are inhibitory receptors. The clinical activity of antibodies that block any of these receptors means that anti-tumor immunity can be enhanced at multiple levels and combinatorial strategies can be leadly designed by mechanistic considerations and preclinical models. do.

The two ligands for PD1 are PD1 ligand 1 (also known as PDL1, B7-H1 and CD274) and PDL2 (also known as B7-DC and CD273). PDL1 is expressed on cancer cells and inhibits T cell activation / function by binding to its receptor PD1 on T cells.

Lymphocyte activation gene 3 (also known as LAG3, CD223), 2B4 (also known as CD244), B and T lymphocyte attenuator (also known as BTLA, CD272), T. The family of cell membrane protein 3 (TIM3, also known as HAVcr2), adenosine A2a receptor (A2aR), and killer inhibitory receptor, respectively, inhibits lymphocyte activity and, in some cases, induces lymphocyte anergy. Is related to. Targeting antibodies to these receptors can be used in the methods of the invention.

Agents that actuate immunoco-stimulatory molecules are also useful in the methods of the invention. Such agents include agonists or CD40 and OX40. CD40 is a co-stimulatory protein found on antigen presenting cells (APCs) and is required for their activation. These APCs include phagocytic cells (macrophages and dendritic cells) as well as B cells. CD40 is part of the TNF receptor family. The major activation signaling molecules for CD40 are IFNγ and CD40 ligand (CD40L). Stimulation with CD40 activates macrophages.

Anti-CCR4 (CD194) antibodies of interest include humanized monoclonal antibodies against CC chemokine receptor 4 (CCR4), which have potential anti-inflammatory and antitumor activity. CCR2 is expressed on inflammatory macrophages, which can be found in various inflammatory conditions, such as rheumatoid arthritis, and has been identified as being expressed on tumor-promoting macrophages. CCR2 is also expressed on regulatory T cells, and the CCR2 ligand CCL2 mediates the recruitment of regulatory T cells to tumors. Regulatory T cells suppress the response of antitumor T cells, and therefore inhibition or deficiency of them is desired.

The protein-producing antibodies of the invention can be prepared by chemical synthesis, but typically, for example, co-expression of all chains constituting the protein in a single recombinant host cell, or heavy chain polypeptides and antibodies ( For example, it is produced by a method of recombinant DNA technology such as co-expression of human antibody). In addition, the heavy and light chains of the antibody can also be expressed using a single polycistronic expression vector. Purification of individual polypeptides is accomplished using standard protein purification techniques such as affinity (protein A) chromatography, size exclusion chromatography and / or hydrophobic interaction chromatography. Bispecific substances differ widely in size and hydrophobicity, and purification can be performed using standard procedures.

The amount of antibody and heavy chain polypeptide produced in a single host cell appears to favor homodimerization over heterodimerization, for example by introducing self-complementary interactions. In addition, WO98 / 50431 for possibilities that can be minimized (eg, "protrusion into the cavity" strategy (see WO 96/27011)) through manipulation of constant regions of antibodies and heavy chains. Please refer to). Accordingly, another aspect of the invention is to provide a method of producing a bispecific substance in a recombinant host cell, wherein the method comprises at least two heavy chain polypeptides in the recombinant host cell. The heavy chain polypeptide comprises the step of expressing the encoding nucleic acid sequence and is different in their constant region sufficiently to reduce or prevent homodimer formation but increase bispecific formation.

If the protein contains three chains (eg, FlicAb), they can be produced by co-expression of the three chains (two heavy chains and one light chain) that make up the molecule in a single recombinant host cell. ..

For recombinant production of the proteins herein, one or more nucleic acids encoding all strands, such as 2, 3, 4, etc., have been isolated for further cloning (amplification of DNA) or expression. Inserted into a replicable vector. Many vectors are available. Vector components generally include, but are not limited to, a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and one or more of transcription termination sequences.

In a preferred embodiment, the host cell according to the method of the invention does not require amplification of a single-strand encoding nucleic acid molecule in the host cell and is high level human immunoglobulin, ie at least 1 pg / cell / day. Expression is preferably at least 10 pg / cell / day, more preferably at least 20 pg / cell / day, or more.

Pharmaceutical Compositions Another aspect of the invention is to provide a pharmaceutical composition comprising one or more proteins of the invention mixed with a suitable pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers used herein are not limited to those used in the art to retain an adjuvant, solid carrier, water, buffer, or therapeutic ingredient. Carriers, or combinations thereof, are exemplified.

The therapeutic formulations of proteins used according to the invention are the proteins of the desired purity, eg, in the form of lyophilized formulations or aqueous solutions, with any pharmaceutically acceptable carrier, excipient, or stabilizer. Prepared for preservation by mixing (see, eg, Rementton's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Acceptable carriers, excipients or stabilizers are non-toxic to the recipient at the doses and concentrations used and are buffers such as phosphates, citrates, and other organic acids, ascorbic acid and methionine. Contains antioxidants, preservatives (octadecyldimethylbenzylammonium chloride, hexamethonium chloride, benzalkonium chloride, benzethonium chloride, phenol, butyl or benzyl alcohol, alkylparabens such as methyl or propylparaben, catechol, resorcinol, cyclohexanol, Low molecular weight (less than about 10 residues) polypeptides (eg, 3-pentanol and m-cresol), proteins such as serum albumin, gelatin or immunoglobulin, hydrophilic polymers such as polyvinylpyrrolidone, glycine, glutamine, asparagine. , Amino acids such as histidine, arginine, or lysine, monosaccharides, disaccharides, and other carbohydrates including glucos, mannose or dextrin, killer agents such as EDTA, scrolls, mannitoles, trehalos. -Sugars or sorbitols, salt-forming counterions such as sodium, metal complexes (eg, Zn-protein complexes), and / or TWEEN ™, PLURONICS ™ or polyethylene glycol (PEG). Contains non-ionic surfactants such as.

The anti-CD3 antibody preparation is disclosed, for example, in US Patent Publication No. 20070065437, the entire disclosure of which is incorporated herein by reference in particular. Similar formulations can be used for the proteins of the invention. The main components of such formulations are PH buffers, salts, surfactants effective in the range 3.0-6.2, and effective amounts of bispecific substances with anti-CD3 specificity.

Methods of Use In particular, when the antigen-binding composition is a multispecific antibody suitable for the condition to be treated, for example, for the treatment of related cancer cells, one binding moiety (of the treatment of related infectious diseases). Therefore, if the specific binding moiety to the pathogen of interest, etc.) specifically binds to the tumor-related antigen, it is limited in the regimen comprising contacting the target cell with the antigen-binding composition of the present invention. Although not, methods are provided for treating or alleviating diseases, including infectious diseases, autoimmune diseases, primary or metastatic cancers, and the like. Such methods include, but are not limited to, administering a therapeutically effective amount or an effective amount of the agent of the invention to a subject in need of treatment, including, but not limited to, reagents and chemotherapeutic agents, radiation therapy, or. Includes combination with surgery.

Effective amounts of the compositions of the invention for the treatment of disease include the means of administration, the target site, the physiological condition of the patient, whether the patient is human or animal, whether other drugs are being administered, and. Depends on many different factors, including whether the treatment is prophylactic or therapeutic. Patients are usually human, but non-human mammals (eg, companion animals such as dogs, cats, horses, experimental mammals such as rabbits, mice, rats, etc.) can also be treated. Therapeutic doses can be incremented to optimize safety and efficacy.

The dose level can be readily determined by a clinician with conventional skills and can be modified as needed, eg, to modify the subject's response to treatment. The amount of active ingredient that can be combined with the carrier material to produce a single dosage form will vary depending on the host being treated and the particular method of administration. Dosing unit forms generally contain from about 1 mg to about 500 mg of active ingredient.

In some embodiments, the therapeutic dose of the agent may range from about 0.0001 to 100 mg / kg of host body weight, more generally 0.01 to 5 mg / kg. For example, the dosage can be in the range of 1 mg / kg body weight or 10 mg / kg body weight, or 1-10 mg / kg. An exemplary treatment regimen involves administration once every two weeks, once a month, or once every 3-6 months. The therapeutic agents of the invention are usually administered on multiple occasions. The interval between single doses can be weekly, monthly, or yearly. The intervals may be irregular, as indicated by measuring the blood concentration of the patient's therapeutic material. Alternatively, the therapeutic agent of the invention may be administered as a sustained release formulation, in which case a smaller number of doses is required. Dosing and frequency will vary depending on the half-life of the polypeptide in the patient.

In prophylactic applications, relatively low doses can be administered over a long period of time at relatively rare intervals. Some patients continue to be treated for the rest of their lives. In other therapeutic applications, relatively high doses are required at relatively short intervals until the progression of the disease is reduced or terminated, and preferably until the patient exhibits partial or complete improvement in the symptoms of the disease. May be said. The patient can then be administered with a prophylactic control regime.

In yet another embodiment, the methods of the invention treat, alleviate or prevent tumor growth, tumor metastasis or tumor infiltration of hematologic cancers such as carcinomas, leukemias and lymphomas, tumors such as melanomas, sarcomas, gliomas. including. For prophylactic use, the pharmaceutical composition or drug is a biochemical, histological, and / or behavioral condition of the disease (its complications and intermediate pathological phenotypes that appear during the course of the disease). At risk of disease or otherwise at risk of disease in sufficient quantities to eliminate or reduce the risk of the disease, including symptoms, reduce the severity of the disease, or delay the onset of the disease Administered to the patient.

Compositions for the treatment of disease can be administered by parenteral, topical, intravenous, intratumoral, oral, subcutaneous, arterial, intracranial, intraperitoneal, intranasal, or intramuscular means. Typical routes of administration are intravenous or intratumor, but other routes may be equally effective.

Typically, the composition is prepared as an injection, either as a liquid solution or a suspension, and a solid form suitable for the solution or suspension in a liquid vehicle prior to injection can also be prepared. As described above, the preparation can be emulsified or encapsulated in liposomes or microparticles such as polylactide, polyglycolide, or copolymer due to the enhanced adjuvant effect (Langer, Science 249: 1527, 1990). , And Hanes, Advanced Drug Delivery Reviews 28: 97-119, 1997). The agents of the invention may be administered in the form of depot injection or implant preparation, which may be formulated in a manner that allows sustained or pulsed release of the active ingredient. Pharmaceutical compositions are generally sterile, substantially isotonic, and formulated in full compliance with all Good Manufacturing Practice (GMP) regulations of the US Food and Drug Administration.

The toxicity of the proteins described herein is cell culture or experimental, eg, by determining LD ₅₀ (a dose that is lethal to 50% of the population) or LD ₁₀₀ (a dose that is lethal to 100% of the population). It can be determined by standard pharmaceutical procedures in animals. The dose ratio between toxicity and therapeutic effect is the therapeutic index. The data obtained from these cell culture assays and animal studies can be used in formulating non-toxic dose ranges for use in humans. The doses of the proteins described herein are preferably within the range of circulating concentrations, including effective doses with little or no toxicity. The dosage may vary within this range, depending on the mode of administration used and the route of administration utilized. The exact formulation, route of administration, and dosage may be selected by the individual physician, taking into account the patient's condition.

The pharmaceutical composition can be administered in various unit dosage forms, depending on the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powders, tablets, pills, capsules, and lozenges. It is recognized that the compositions of the invention should be protected from digestion when administered orally. This is typically done by complexing the molecules with the composition to make them resistant to acidic and enzymatic hydrolysis, or by making the molecules into appropriately resistant carriers such as liposomes or protective barriers. Achieved by packaging. Means of protecting the drug from digestion are well known in the art.

The composition for administration usually comprises a pharmaceutically acceptable carrier, preferably an antibody or other ablation agent dissolved in an aqueous carrier. Various aqueous carriers such as buffered saline can be used. These solutions are sterile and generally free of unwanted substances. These compositions may be sterilized by conventional well-known sterilization techniques. The composition is pharmaceutically necessary to approximate the physiological conditions of PH regulators and buffers, toxicity regulators, etc., such as, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc. May contain acceptable auxiliary substances. The concentration of the active agent in these formulations can vary widely and will be selected primarily on the basis of fluid volume, viscosity, body weight, etc., according to the particular mode of administration selected and the needs of the patient. Deaf (eg, Remington's Pharmacological Science (15th ed., 1980), and Goodman & Gillman, The Pharmacological Basis of Therapeutics (Hardman 96 et.).

Within the scope of the present invention, there are also a kit containing the activator of the present invention and a preparation thereof, and instructions for use. The kit may further include at least one additional reagent, such as a chemotherapeutic agent. The kit typically includes a label indicating the intended use of the contents of the kit. The term label includes any description or recorded material that is supplied on or with the kit or otherwise accompanies the kit.

The composition can be administered for therapeutic treatment. The composition is administered to the patient in an amount sufficient to substantially excise the target cells, as described above. An amount sufficient to achieve this is defined as a "therapeutically effective dose" that can result in an improvement in overall survival. Single or multiple doses of the composition may be administered depending on the dose and frequency required and tolerated by the patient. The specific dose required for treatment depends on the medical condition and history of the mammal, as well as other factors such as age, weight, gender, route of administration, efficiency and the like.

Although the invention has been fully described, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the spirit or scope of the invention.

Example 1
Genetically engineered rat human IgH loci expressing heavy chain-only antibodies are constructed in several parts, including modification and linkage of the rat C region gene linked downstream of the human _VH 6- _DJH region. And assembled. Two BACs with separate clusters of the human _VH gene were then injected simultaneously with the BAC encoding the assembled (human _VH 6- _DJH -rat C) fragment.

Transgenic rats carrying the artificial heavy chain immunoglobulin locus in an unrearranged state were generated. The genes in the constant regions included encode IgM, IgD, IgG2b, IgE, IgA and 3'enhancers. RT-PCR and serum analysis (ELISA) of transgenic rats revealed productive rearrangement of the transgenic immunoglobulin locus and expression of antibodies in serum with only heavy chains of various isotypes. Transgenic rats were mated with rats bearing the mutated endogenous heavy and light chain loci previously described in US Patent Publication No. 2009/098134 A1. Analysis of such animals showed inactivation of heavy and light chain expression in rat immunoglobulins, as well as high levels of expression of heavy chain antibodies with variable regions encoded by the human V, D and J genes. rice field. Immunization of transgenic rats resulted in the production of high titers of antigen-specific heavy chain antibodies. These transgenic rats expressing heavy chain antibodies with human VDJ regions were called UniRats.

Example 2
Genetically engineered rat transgenic human antibody repertoires expressing immobilized light chain antibodies are generated from H chains with diverse ( _VH - _DJH ) _n rearrangements in combination with the unique L chain. rice field. To this end, reorganized L-chain human Vk-Jk1-Ck was incorporated into the rat germline by DNA microinjection and the resulting transgenic animals were previously described as previously described to express the human H-chain repertoire naturally. (Osborn et al., 2013). This new rat strain was named OmniFlic.

Immunization of OmniFlic rats with many different antigens produced high levels of antigen-specific IgG, similar to other transgenic rats with the same IgH locus. Repertoire analysis by RT-PCR identified highly variable _VH gene rearrangements at high transcript and protein levels. In addition, only one L-chain product was identified that was also expressed at high levels.

Antigen-specific binders from OmniFlic were obtained by selection from NGS and cDNA libraries (yeast, E. coli, phage), and various H-chain transcripts were identified during sequencing. For expression in mammalian cells, the hypermutant H chain construct was transfected in combination with the original transgenic Igk sequence. In this rearranged Vk-Jk1-Ck, no mutational changes were observed and the same L chain was always expressed with various H chain products to produce monoclonal human IgG.

Example 3
Generation of Antigen-Specific Antibodies in Transgenic Rats Genetically engineered expression rats were immunized in two ways to generate antigen-specific heavy chain antibodies in rats.

Immunization using recombinant extracellular domains of PD-L1 and BCMA. Recombinant extracellular domains of PD-L1 and BCMA were purchased from R & D Systems, diluted with sterile saline and combined with an adjuvant. The immunogen was a combination of either complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA), or Tittermax and Ribi adjuvant. Initial immunization (priming) using an immunogen in CFA or Tittermax was administered to the left and right legs. After the first immunization with an immunogen in CFA, two or more immunizations with IFA (boost immunization), or four or more immunizations with Ribi, and another immunization with Tittermax were administered to each leg. This series of immunity results in the development of B cells that produce high affinity antibodies. The concentration of immunogen was 10 micrograms per leg. Serum was taken from rats at the final blood draw to determine serum titers.

Genetically engineered rats were immunized using a DNA-based immunization protocol for the production of anti-human CD3δε antibody.

OmniFlic rats were subjected to GENOVAC antibody technology using Aldevron, Inc. (Fargo, ND) was immunized with the CD3-epsilon / delta construct of human and cynomolgus monkeys. After final booster immunization and RNA isolation, inflow region lymph nodes were harvested. After cDNA synthesis, the IgH heavy chain antibody repertoire was characterized by next-generation sequencing and proprietary in-house software. Candidate antigen-specific VH sequences showing evidence of antigen-specific positive selection were selected. Hundreds of VH sequences encoding FlicAbS were selected for gene recombination and cloned into expression vectors. Subsequently, fully human human FlicAb IgG1 antibody was expressed in HEK cells for flow and ELISA analysis. Human FlicAb was tested for binding to primary human T cells and Jurkat cells by flow. In addition, human FlicAb was tested in ELISA using recombinant CD3δε protein. All FlicAbs with positive binding to human T cells are listed in FIGS. 1 and 2. The selected sequences were further characterized in the T cell activation assay.

Example 4 Antibody Features The data table in FIG. 3 summarizes the behavior of Family 2 anti-CD3 antibodies in monospecific and bispecific formats. Column 1 shows the sequence ID of the anti-CD3 VH sequence. Column 2 shows the MFI values for Jurkat cell junctions of parental monospecific anti-CD3. Column 3 shows the MFI values for cynomolgus monkey T cell binding of parental monospecific anti-CD3. Column 4 shows the names of aCD3: aBCMA bispecific antibodies. Column 5 shows a picogram of IL-2 released by pan-T cells stimulated by a bispecific antibody that binds to a plastic-coated BCMA protein at the indicated dose. Column 6 shows a picogram of IL-6 released by pan-T cells stimulated by a bispecific antibody that binds to a plastic-coated BCMA protein at the indicated dose. Column 7 shows a picogram of IL-10 released by pan-T cells stimulated by a bispecific antibody that binds to a plastic-coated BCMA protein at the indicated dose. Column 8 shows a picogram of IFNγ released by pan-T cells stimulated by a bispecific antibody that binds to a plastic-coated BCMA protein at the indicated dose. Column 9 shows a picogram of TNFα released by pan-T cells stimulated by a bispecific antibody that binds to a plastic-coated BCMA protein at the indicated dose. Column 10 shows _EC50 of bispecific antibody-mediated U266 tumor cytolysis in the presence of human pan-T cells. Column 11 shows the lysis percent of U266 tumor cells at a dose of 333 ng / mL bispecific antibody in the presence of bispecific antibody and human pan-T cells. Column 12 shows the protein binding affinity of the anti-CD3 arm of the bispecific antibody as measured by the octet. Column 13 shows MFI values for Jurkat cell binding of bispecific antibodies.

Example 5 Characterizing Bispecific Antibodies U266 BCMA + tumors of seven αCD3_fam2: aBCMA bispecific antibodies, each with a unique anti-CD3 arm and a common anti-BCMA arm, through redirection of activated primary T cells. The ability to kill cells was tested. In this experiment, BCMA expressing U266 cells were mixed with activated pan-T cells in a 10: 1 E: T ratio with the addition of bispecific antibody. As shown in FIG. 4, the X-axis shows the concentration of the antibody used and the Y-axis shows the% lysis of the tumor cells 6 hours after the addition of the antibody.

A comparison of bispecific antibody-mediated tumor cytolytic activity with IL-2 cytokine release is shown in the scatter plot of FIG. The correlation between IL-2 production and lysis of U266 tumor cells is R ² = 0.37. A comparison of bispecific antibody-mediated tumor cytolytic activity and IFN-γ cytokine release is shown in the scatter plot of FIG. The correlation between IFN-γ production and U266 tumor cell lysis is R ² = 0.53. A comparison of bispecific antibody-mediated U266 tumor cytolytic activity with anti-CD3 binding affinity is shown in the scatter plot of FIG. The correlation between EC50 of _U266 killing and protein binding affinity is R ² = 0.93.

Example 6 Tumor Cell Dissolution αCD3_F1F: αBCMA bispecific antibodies were assayed for their ability to kill three different BCMA + tumor cells and one BCMA negative cell line via redirection of activated primary T cells. In this experiment, tumor cells were mixed with activated pan-T cells at a 10: 1 E: T ratio with the addition of bispecific antibodies. The results are shown in FIGS. 8A-6D. Panel A shows the death of RPMI-8226 cells, panel B shows the death of NCI-H929 cells, panel C shows the death of U-266 cells, and panel D shows the death of negative control K562 cells. Is shown. The X-axis shows the concentration of the antibody used, and the Y-axis shows the% lysis of tumor cells 6 hours after the addition of the antibody.

The levels of IL-2 cytokine release measured after resting human T cells were cultured in increasing doses of various tumor cell lines and αCD3_F1F: αBCMA bispecific antibodies are shown. FIG. 9A shows the release of IL-2 stimulated by RPMI-8226 cells, FIG. 9B shows the release of IL-2 stimulated by NCI-H929 cells, and FIG. 9C shows the release of IL-2 stimulated by U-266 cells. Showing the released IL-2, FIG. 9D shows the release of IL-2 stimulated by the negative control K562 cells.

The levels of IFNγ cytokine release measured after resting human T cells were cultured in increasing doses of various tumor cell lines and αCD3_F1F: aBCMA bispecific antibodies are shown. FIG. 10A shows the release of IFNγ stimulated by RPMI-8226 cells, FIG. 10B shows the release of IFNγ stimulated by NCI-H929 cells, and FIG. 10C shows the release of IFNγ stimulated by U266 cells. Shown, FIG. 10D shows the release of IFNγ stimulated by the negative control K562 cells.

The examples are presented to those skilled in the art to provide full disclosure and description of the methods of manufacture and use of the invention, and are intended to limit the scope of what the inventors consider to be their inventions. Nor is it intended to represent that the following experiments are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to the numbers used (eg, quantity, temperature, etc.), but some experimental errors and deviations should be considered. Unless otherwise stated, parts are parts by weight, molecular weights are weight average molecular weights, temperatures are in degrees Celsius, and pressures are at or near atmospheric pressure.

Although the invention has been described with reference to its particular embodiments, it will be appreciated by those skilled in the art that various modifications and equivalents can be made without departing from the true spirit and scope of the invention. It should be. In addition, many modifications may be made to adapt a particular situation, material, composition of substance, process, process step or steps to the object, spirit and scope of the invention. All such amendments are intended to be within the scope of the appended claims.

Claims (53)

A heavy chain variable domain containing the sequence of SEQ ID NO: 1 or a heavy chain variable domain containing the sequence of SEQ ID NO: 13.
A light chain variable domain comprising the sequence of SEQ ID NO: 19 and
A multispecific antibody comprising a first binding moiety having binding specificity for CD3, comprising: The heavy chain variable domain of the first binding moiety comprises a sequence having at least 95% identity with SEQ ID NO: 1; and the light chain variable domain of the first binding moiety contains at least 95% with SEQ ID NO: 19. Containing sequences with the same identity,
The multispecific antibody according to claim 1 . The heavy chain variable domain of the first binding moiety comprises a sequence having at least 95% identity with SEQ ID NO: 13; and the light chain variable domain of the first binding moiety contains at least 95% with SEQ ID NO: 19. Containing sequences with the same identity,
The multispecific antibody according to claim 1 . The heavy chain variable domain of the first binding moiety comprises the sequence of SEQ ID NO: 1; and the light chain variable domain of the first binding moiety comprises the sequence of SEQ ID NO: 19.
The multispecific antibody according to claim 2 . The heavy chain variable domain of the first binding moiety comprises the sequence of SEQ ID NO: 13; and the light chain variable domain of the first binding moiety comprises the sequence of SEQ ID NO: 19.
The multispecific antibody according to claim 3 . The multispecific antibody according to any one of claims 1 to 5 , further comprising a second binding moiety having binding specificity for a protein other than CD3. The multispecific antibody of claim 6 , wherein the second binding moiety comprises a single heavy chain variable region in a single or tandem configuration. The multispecific antibody according to claim 6 , wherein the first binding moiety comprises a light chain polypeptide subunit and a heavy chain polypeptide subunit, and the second binding moiety comprises a heavy chain polypeptide subunit. The multispecific antibody according to claim 8 , wherein the light chain polypeptide subunit of the first binding moiety comprises a light chain constant domain. The multispecific antibody of claim 8 , wherein the heavy chain polypeptide subunit of the first binding moiety comprises at least one heavy chain constant domain. The multispecific antibody according to claim 10 , wherein the heavy chain polypeptide subunit of the first binding moiety comprises a CH1 domain, a CH2 domain and a CH3 domain. 11. The multispecific antibody of claim 11 , wherein the heavy chain polypeptide subunit of the first binding moiety comprises a hinge region located between the CH1 and CH2 domains. The multispecific antibody of claim 8 , wherein the heavy chain polypeptide subunit of the second binding moiety comprises at least one constant domain. The multispecific antibody according to claim 13 , wherein the heavy chain polypeptide subunit of the second binding moiety comprises a CH2 domain and a CH3 domain but does not contain a CH1 domain. The multispecific antibody according to claim 13 or 14 , wherein the heavy chain polypeptide subunit of the second binding moiety comprises a hinge region located between the second binding site and the CH2 domain. 23. 11-15 , wherein the CH2 and CH3 domains of the heavy chain polypeptide subunit of the first binding moiety and the CH2 and CH3 domains of the heavy chain polypeptide subunit of the second binding moiety together form an Fc region. The multispecific antibody according to any one of the above items. The multispecific antibody according to claim 16 , wherein the Fc region comprises a naturally occurring sequence human IgG1 Fc region. The multispecific antibody according to claim 16 , wherein the Fc region comprises a mutant human IgG1 Fc region. The multispecific antibody of claim 18 , wherein the mutant human IgG1 Fc region is engineered to reduce one or more effector functions. The multispecific antibody of claim 16 , wherein the Fc region comprises a native sequence human IgG4 Fc region. The multispecific antibody according to claim 16 , wherein the Fc region comprises a mutant human IgG4 Fc region. 21. The multispecific antibody of claim 21 , wherein the mutant human IgG4 Fc region is engineered to reduce one or more effector functions. The multispecific antibody according to any one of claims 16 to 22 , wherein the Fc region is engineered to reduce homodimer formation. The multispecific antibody according to any one of claims 6 to 23 , wherein the second binding moiety has binding specificity for a protein other than CD3. The multispecific antibody according to claim 24 , wherein the protein other than CD3 is a tumor-related antigen (TAA) or a tumor-specific antigen (TSA). 25. The multispecific antibody of claim 25 , wherein TAA is a B cell maturation antigen (BCMA). A pharmaceutical composition comprising the multispecific antibody according to any one of claims 1 to 26 . The polynucleotide encoding the multispecific antibody according to any one of claims 1 to 26 . A vector comprising the polynucleotide according to claim 28 . A cell comprising the vector according to claim 29 . The invention according to any one of claims 1 to 26 , which comprises proliferating the cell according to claim 30 and isolating the multispecific antibody from the cell under conditions that allow the expression of the multispecific antibody. A method for producing a multispecific antibody of. A pharmaceutical for use in the treatment of a disease or condition in an individual in need comprising an effective amount of the multispecific antibody according to any one of claims 1 to 26 or the pharmaceutical composition according to claim 27 . The medicine according to claim 32 , wherein the disease is an autoimmune disease. The medicine according to claim 32 , wherein the disease is cancer. For treating a disease or disorder in an individual in need thereof, comprising the multispecific antibody according to any one of claims 1 to 26 or the pharmaceutical composition according to claim 27 , and instructions for use. kit. 35. The kit of claim 35 , further comprising at least one additional reagent. 36. The kit of claim 36 , wherein the at least one additional reagent comprises a chemotherapeutic agent. SEQ ID NO: With a first polypeptide subunit comprising a light chain variable domain (VL) and a light chain constant domain (CL) comprising the sequence of SEQ ID NO: 19;
(I) SEQ ID NO: 1 sequence; or (ii) Heavy chain variable domain (VH) containing SEQ ID NO: 13 and heavy chain subunits including CH1 domain, hinge region, CH2 domain and CH3 domain (ii). A second polypeptide subunit containing CH),
With a second polypeptide subunit that together the light chain variable domain and the heavy chain variable domain form a first binding site with binding specificity for CD3;
A single heavy chain variable region in a single or tandem configuration with binding specificity for proteins other than CD3, and a heavy chain constant domain containing the hinge region, CH2 domain and CH3 domain in the absence of the CH1 domain. With a third polypeptide subunit, including (CH);
A bispecific triple-stranded antibody-like molecule, including. 23. 2 of claim 38 , wherein the heavy chain constant domain of the second polypeptide subunit and the heavy chain constant domain of the third polypeptide subunit are engineered to reduce one or more effector functions. Heavy-specific triple-stranded antibody-like molecule. 38 or 39 , wherein the heavy chain constant domain of the second polypeptide subunit and the heavy chain constant domain of the third polypeptide subunit are engineered to reduce homodimer formation. Bispecific triple-stranded antibody-like molecule. The pharmaceutical composition comprising the bispecific triple-stranded antibody-like molecule according to any one of claims 38 to 40 . In the treatment of a disease or condition in an individual in need comprising the effective amount of the bispecific triple chain antibody-like molecule according to any one of claims 38 to 40 or the pharmaceutical composition according to claim 41 . Medicine for use. The medicine according to claim 42 , wherein the disease is an autoimmune disease. The medicine according to claim 42 , wherein the disease is cancer. A disease or disease in an individual in need thereof, comprising the bispecific triple-stranded antibody-like molecule of any one of claims 38-40 or the pharmaceutical composition of claim 41 , and instructions for use. A kit for treating diseases. 45. The kit of claim 45 , further comprising at least one additional reagent. 46. The kit of claim 46 , wherein the at least one additional reagent comprises a chemotherapeutic agent. Use of the effective amount of the multispecific antibody according to any one of claims 1 to 26 or the pharmaceutical composition according to claim 27 in the preparation of a medicine for treating a disease or condition in an individual in need. .. The use according to claim 48 , wherein the disease is an autoimmune disease. The use according to claim 48 , wherein the disease is cancer. 24. The effective amount of the bispecific triple-stranded antibody-like molecule according to any one of claims 38 to 40 or claim 41 in the preparation of a pharmaceutical for the treatment of a disease or condition in an individual in need. Use of pharmaceutical compositions. The use according to claim 51 , wherein the disease is an autoimmune disease. The use according to claim 51 , wherein the disease is cancer.

Images